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Abstract 
Classification of Tissues and Disease Subtypes Using Whole-Genome Signatures 
Michael P. Gormley 
Aydin Tozeren, Ph. D. 
 
 
 
 
Development and application of microarray technology in biological research has led to 
compilation of expression and sequence data on a genome-wide scale.  Given the volume 
of data produced and the complexity of gene regulatory mechanisms, it can be difficult to 
extract meaningful biological information.  Classification can be used to reduce the 
complexity through the detection of genes, genetic loci or conditions that share common 
attributes and the identification of gene expression patterns or genotypes associated with 
phenotype.  In the study of cancer, supervised classification has been applied to identify 
gene expression biomarkers of different disease states.  Clinically validated biomarkers 
are valuable indicators for diagnosis and guiding therapeutic strategy.  We developed an 
iterative machine learning algorithm to compare the predictive value of biomarker sets 
chosen by supervised classification against sets selected randomly from known disease-
related genes.  Both supervised classification and feature selection based on prior 
knowledge resulted in discriminative classification of molecular phenotypes in breast 
cancer and lymphoma.  Compilation of gene expression data has led to the identification 
of genes with bimodal, or switch-like, expression patterns.  We used unsupervised, 
supervised and model-based classification methods to investigate the biological relevance 
of bimodal expression patterns and to evaluate their potential for class discovery and 
prediction.   Both model-based and supervised classification resulted in the accurate 
classification of samples by tissue phenotype or infectious disease.  Functional 
  
xiv 
enrichment analysis indicates switch-like genes are involved in tissue-specific or immune 
response functions.  Taken together, this evidence supports the assertion that bimodal 
expression patterns are biologically relevant.  Clinical relevance of bimodal expression 
patterns was investigated in an association study of genotypes of families affected by 
autism.  A subset of neural-specific switch-like genes was used to identify candidate gene 
regions which may contain genetic variants associated with autism risk.  A two-stage 
family-based association test detected an autism susceptibility locus in the q26 region of 
chromosome 10.   The coding region of the fibroblast growth factor receptor 2 (FGFR2) 
gene is 80 kilobases downstream from the identified locus.  Altered expression of FGFR2 
may be a contributing genetic factor in development of autism.  Identification of the 
susceptibility locus provides motivation for novel hypotheses concerning the molecular 
basis of autism.  In addition, we provide a method for integration of gene expression and 
genotype data that may lead to the identification of disease-related polymorphisms in 
other disorders.     
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Chapter 1: Introduction 
 
 
 
Gene expression is regulated by complex interactions between DNA, regulatory proteins, 
epigenetic mechanisms and microRNA molecules.  Activation and repression of gene 
expression is used to control cellular processes and can also lead to phenotypic changes 
such as tissue differentiation and disease.  Microarray technology provides the means to 
quantify expression and type genetic variation in the DNA sequence at a genome-wide 
scale.  However, the high-dimensionality of microarray datasets along with relatively 
small samples sizes hinders the effectiveness of microarray analysis.  In this work, we 
have used a variety of classification methodologies to address critical issues in the field 
of microarray analysis and extract meaningful biological information.  
 
Gene expression biomarkers are highly valued in the prediction of prognosis of 
heterogeneous disease.  Supervised classification methods, such as k-nearest neighbor, 
linear discriminant analysis and support-vector machines, have been applied to gene 
expression microarray data in order to identify biomarkers at high-throughput.  The lack 
of commonly shared genes among independent biomarker panels of the same disease 
state raises questions concerning the power and reproducibility of differential expression 
analysis.  To address these questions, we developed a machine learning algorithm to 
generate and validate populations of gene expression biomarker panels from microarray 
data.  With this approach, we identified many gene sets that are predictive of molecular 
subtype in breast cancer and lymphoma.  In addition, we observed that the accuracy of 
classification decreases and the variance in accuracy increases when evaluating 
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biomarker sets across platforms.  From this analysis, we conclude that the lack of 
agreement between independently derived biomarker panels is due in part to the number 
of relevant genes and technical variation between microarray platforms.  These results 
have important consequences in the experimental design and interpretation of microarray 
experiments.  
 
Gene expression profiling of diverse phenotypes in health and disease allow us to identify 
common modes of gene expression.  For example, housekeeping genes have been 
identified which are constitutively expressed across tissues and tend to be involved in a 
minimal set of structures and processes required for cellular viability.  In previous work, 
we identified a set of switch-like genes with bimodal expression patterns across 19 
different tissue types.  In this work, we investigated the expression profiles of these 
switch-like genes in both health and infectious disease.  Both model-based and multi-
class supervised classification accurately categorized tissue samples according to tissue 
type and infectious disease.  In addition, functional enrichment analysis indicated that 
activated switch-like genes in different phenotypes are involved in specialized tissue-
specific or immune response functions.  Through our application of advanced 
classification algorithms along with the use of gene functional information, we conclude 
that switch-like genes represent a biologically relevant subset of genes that warrant 
further study.   In addition, due to the accurate classification of phenotypes in a multi-
class setting, we contend that the identification of switch-like genes may be a useful 
dimension reduction method in future analysis of expression data.  
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Use of gene sequencing arrays for the identification of single nucleotide polymorphisms 
associated with susceptibility to disease is burdened by a large multiple testing problem.  
Thresholds for genome-wide significance must be adjusted to account for the number of 
hypotheses tested.  We used our insight on switch-like genes to reduce the number of 
hypotheses up front by identifying candidate gene regions in an association study of 
autism.  Specifically, we scanned the coding and cis-regulatory regions of neural-specific 
switch-like genes for genetic variants associated with autism susceptibility.  Using a two-
stage family-based association test, we identified an autism susceptibility locus in an 
intergenic region of chromosome 10.  The locus is approximately 80 kilobases upstream 
of the fibroblast growth factor receptor 2 (FGFR2) gene.  Fibroblast growth factor 
signaling is involved with both neurodevelopment and neural proliferation in the adult 
brain.  Our results suggest that altered expression patterns of FGFR2 due to genetic 
variation at the autism susceptibility locus may contribute to increased risk of disease.   
This study provides a novel method for the integration of gene expression and gene 
sequence data in genome-wide association study.  In addition, the identification of the 
autism susceptibility locus and the potential involvement of FGFR2 provides motivation 
for biologists to test new hypotheses regarding the molecular basis of autism.  
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Chapter 2: Background 
 
This chapter describes biological processes related to gene regulation in health and 
disease.  Microarray platforms capable of measuring gene expression and characterizing 
gene sequence are discussed.  In addition, databases that have compiled information on 
genes and gene products are reviewed.  
 
 
2.1 Molecular biology of gene regulation 
Cellular function is governed by the production, interaction, modification and 
degradation of proteins generated from genetic information stored in the nucleus.  
Genetic information is stored as DNA, a highly ordered configuration of polymer strings 
of nucleotides arranged in a double helix formation.  Association of DNA with histone 
protein complexes allows for tight packing and organization of the genetic information 
[1].   Genes and regulatory regions are identified by specific sequences of nucleotide 
bases.  Alterations in the genetic sequence caused by copying errors, environmental 
effects [2], or viral infection [3] can result in the alteration of the structure and function 
of gene products.  The central dogma of molecular biology describes the process by 
which genetic information encoded in the DNA sequence is first transcribed into RNA 
and then translated into polypeptides.  This process is strictly regulated to control which 
gene products are expressed under which conditions.   
 
Transcription is the production of RNA molecules from the coding regions of the DNA 
sequence.   Transcription is initiated by the binding of a protein complex of basal 
transcription factors and RNA polymerase to the DNA at a specific recognition site 
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upstream of the gene coding region [4].  Binding of additional transcription factors to 
upstream or downstream regulatory regions of the DNA amplifies the rate of 
transcription.  Transcription factor activity can be regulated by several processes 
including protein synthesis, subcellular localization [5], ligand binding [6], dimerization 
[7], and phosphorylation [8].  In addition, the relationship of transcription factors to the 
genes they regulate is often many to many.  These characteristics of transcriptional 
regulation allow for fine control of gene expression.  Following transcription, synthesized 
RNA is processed into messenger RNA (mRNA) by removing non-coding regions, and 
capping the 5’ and 3’ ends of the transcript.  Alternative splicing at this stage results in 
greater variation in the protein population and allows for additional regulation of gene 
expression [9].   
 
Transcribed mRNA carries genetic information from the nucleus to the cytoplasm where 
it serves as a template in the formation of amino acid peptide chains that constitute the 
primary structure of proteins.  Amino acids are represented by sets of nucleotide triplets 
in the mRNA sequence known as codons [4].  Additionally, start and stop codons signal 
for the initiation and termination of protein synthesis.  Transfer RNAs are oligonucelotide 
molecules with sites for codon recognition and amino acid binding.  Ribosomes induce 
translation by providing a site for the interaction of the mRNA transcript with transfer 
RNAs and catalyzing the formation of peptide bonds between sequential amino acids.  
Following translation, synthesized polypeptides fold into native, three-dimensional 
structures that confer protein activity.   
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Figure 1: Transcription and translation [10] 
 
 
 
Protein function can be altered by post-translational modifications.   Modifications 
include the addition and removal of functional groups (e.g. phosphorylation, acetylation), 
covalent linkage to other proteins (e.g. ubiquitinylation) and the formation and cleavage 
of additional bonds between amino acids [11].  Kinases and phosphatases are enzymes 
which add or remove phosphate groups to serine, threonine or tyrosine residues of 
proteins [4].  Phosphorylation can change the activity of a protein through the blocking or 
formation of active sites or other conformational changes.  Protein degradation is 
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regulated by covalent binding of ubiquitin to lysine residues of the target protein.  
Ubiquitinylation marks proteins for degradation by proteolytic protein complexes.  A 
number of proteins are synthesized in inactive forms.  Activation occurs by formation or 
cleavage of bonds between amino acid residues [12].  Modifications such as these enable 
dynamic regulation of protein function at the post-translational stage. 
 
Gene expression is also controlled by epigenetic mechanisms independent of gene 
sequence.  Methylation of cytosine CpG dinucleotide sequences maintains gene 
expression patterns across cell division cycles and plays an important role in development 
[13, 14].  Distribution of CpG dinucelotides in the genome is disproportionately biased 
towards gene coding regions and transcription start sites [15].  DNA methylation 
surpresses transcription of associated genes through direct or indirect inhibition of 
transcription factor DNA binding [14].   Additional epigenetic mechanisms include 
histone modifications and chromatin remodeling.  Phosphorylation, acetylation, and 
methylation of residues of the N-terminal histone tail alter the configuration of the DNA 
sequence to make it accessible for transcription [16].  Similarly, chromatin remodeling 
proteins use energy gained from ATP hydrolysis to dissociate DNA from histone 
complexes [16, 17].  Epigenetic mechanisms provide additional means of regulating the 
process of gene expression.  
 
Association of mRNA transcripts with microRNAs (miRNA) provides regulation of gene 
expression at the post-transcriptional level.  MicroRNAs are 21-25 nucelotide RNA 
molecules that bind with complimentary sequences in the 3’ untranslated region of 
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mRNA transcripts [18].  Precursor microRNAs are transcribed in an inactive hairpin 
form.  Production of mature microRNAs is catalyzed by two ribonuclease enzymes that 
yield the 21-25 base pair active form [19, 20].  Active microRNAs form a RNA-induced 
silencing complex (RISC) by association with proteins in the argonaute family [21].  In 
most conditions, binding of the RISC to the target mRNA represses gene expression by 
one of two mechanisms: either translational inhibition or destabilization of the target 
transcript through removal of the 3’ polyamine cap [18].  Recent work has demonstrated 
that some miRNA-protein complexes may upregulate translation in growth arrested 
conditions [22].  Regardless of the effect on translation, miRNA-mediated effects result 
in transcript-specific regulation of expression. 
 
2.2 Single-nucleotide polymorphisms 
Single-nucleotide polymorphisms (SNPs) are variations in the genetic sequence 
consisting of a single nucleotide base substitution.  Approximately four million SNPs 
distributed at an average density of one SNP per kilobase throughout the genome have 
been identified [23].  Genotyping efforts suggest that a majority of the genetic diversity 
between two individuals is captured by SNPs.  Correlation between genetic variants 
arises as a result of common genetic history.  Mutations are initially inherited together 
with alleles on the same chromosome.  Linkage between alleles degrades over time by 
recombination and mutation, but extensive genotyping of single nucleotide 
polymorphisms in four genetically diverse populations through the International HapMap 
Project has identified common haplotypes (i.e. chromosomal loci that tend to be 
transmitted together) [HapMap, 2005; HapMap, 2007] [23, 24].  These studies have also 
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located recombination hotspots where genetic variation occurs with higher frequency.  
This information can be used to genotype a large portion of the genetic sequence with a 
small number of tagSNPs that are highly associated with other SNPs in close proximity.  
 
2.3 Cellular signaling pathways  
 
Cells coordinate internal processes and respond to external stimuli through the use of 
cellular signaling pathways.  Cellular signaling consists of cascades of biochemical 
reactions that act on proteins and small molecules to propagate messages through the cell 
to the nucleus.  Many signaling pathways end in the activation of transcription factors or 
other DNA-binding proteins that then interact with the DNA to induce or repress 
expression of target genes.   
 
The mitogen-activated protein kinase (MAPK) pathway is one of the most actively 
studied signaling pathways.  MAPKs are divided into several major subgroups including 
extracellular signal-regulated kinases (ERK1, ERK2), c-Jun N-terminal kinases (JNK1, 
JNK2, JNK3) and stress-activated protein kinase-2 homologs (p38α, p38β, p38δ) [25, 
26].  Signaling through ERK1/ERK2 pathways regulates cellular proliferation and cell 
division [26].  Activation of JNK pathways is involved with the initiation of apoptosis.   
The p38 MAPK family regulates cell division and gene expression related to osmotic and 
heat shock responses.  In canonical MAPK signaling, MAPKs are activated by a 
phosphorylation cascade through a three-member protein kinase module [27].  For 
example, in ERK signaling, stimuli such as g-protein receptor (Ras) ligand binding 
induce the phosphorylation of an upstream MAP3K (a-Raf, b-Raf, c-Raf1)[28].  
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Activated MAPK3s phosphorylate MAP2Ks (MEK1/MEK2) at two serine residues.  
ERK1,2 is then activated through the phrosphoryaltion of tyrosine and threonine residues.  
Upon activation, ERK1 translocates to the nucleus and activates transcription factors 
including c-Fos, ATF-2, Elk-1, c-Jun, c-Myc, and Ets1.   
 
In addition to signal transduction along canonical pathways, a fair amount of crosstalk 
occurs between MAPK pathways and between MAPK and other canonical pathways.    
Activation of the p38 MAPK pathway inhibits activation of ERK signaling through the 
dephosphorylation of MEK1/2 [28].  In contrast, activation of integrin signaling through 
p21 protein-activated kinase 1 (PAK1) leads to the formation of focal adhesions and the 
phosphorylation of MEK1 [29].  PAK1-mediated phosphorylation enhances the 
association of MEK1 with Raf1 and leads to more efficient activation of ERK signaling 
[29].  Interactions along and between pathways form an elaborate signaling network by 
which cellular processes are integrated and controlled. 
 
2.4 Mendelian and chronic diseases  
 
Deregulation of cellular processes can lead to disease.  Cancer, for example, is 
characterized by uncontrolled cell growth.  Increasing chromosomal instability 
contributes to the accumulation of mutations that lead to advanced stages of disease.  
Mutation of the Ras proto-oncogene is observed in many tumors and causes constitutive 
activation of ERK signaling [26, 30].  Conversely, hypermethylation of CpG islands near 
gene promoters can cause silencing of tumor suppressor genes involved in DNA repair, 
hormone response, p53 signaling, apoptosis and cellular adhesion [31].  These findings 
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Figure 2: Crosstalk between mitogen-activated protein kinase (MAPK) signaling 
pathways.  MAPK pathways are arranged into three-unit modules of protein kinases.  
Stimuli induce activation of downstream MAPKs through a cascade of phophorylation 
reactions.  Context-specific crosstalk is indicated by dashed lines. [28] 
 
 
 
demonstrate that disease is often associated with malfunctions in the cellular regulatory 
mechanism. 
 
Diseases can be loosely grouped into two categories: mendelian and complex disorders.  
Mendelian, or monogenic, disorders are caused by the transmission of a defect at a single 
genetic locus [32, 33].  Examples of mendelian disorders include phenylketonuria, cystic 
fibrosis, Huntington disease, a subset of muscular dystrophies and genes that transmit 
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heritable susceptibility to breast cancer and retinoblastoma [33].  Approximately 1200 
mendelian disease genes have been identified through statistical analysis of the genotypes 
of families that demonstrate the disease phenotype [33].  Once a disease gene has been 
identified, hypotheses regarding the disease mechanism can be generated based on the 
function of the corresponding protein.  Mendelian diseases are relatively rare.  Complex 
disorders, such as cancer, obesity, autism and diabetes, are much more common.  The 
common variant-common disease hypothesis proposes that susceptibility to diseases such 
as heart disease and cancer may be conferred in part by SNPs observed in the majority of 
the population.   In support of this hypothesis, genome-wide association studies have 
identified disease-associated SNPs in many common diseases including rheumatoid 
arthritis, bipolar disorder, coronary artery disease, Crohn’s disease, hypertension, and 
type 1 and type 2 diabetes [34].  Complex disorders are associated with variation at many 
genetic loci as well as environmental and lifestyle factors.  The contribution of multiple 
factors to the onset and progression of complex disorders makes it more difficult to 
isolate the genetic component of etiology. 
 
 
2.5 Microarrays for gene expression and genotyping   
 
Development of microarray platforms for genotyping and measuring gene expression has 
provided a powerful tool in the study of complex disease and other biological 
phenomena.  Arrays consist of ordered arrangements of single-stranded oligonucleotides 
(probes) bound to a solid substrate such as a glass slide or plastic chip.  Current 
technology provides for the representation of over 1 million features on a single array.  
  
13 
Microarray analysis enables genotyping and the quantification of gene expression on a 
near to genome-wide scale.  
 
Gene expression microarrays can be classified into two categories: two-color 
complimentary DNA (cDNA) platforms and high-density oligonucleotide arrays.  Two-
color arrays are generally made in-house by spotting PCR-amplified cDNA probes with a 
robotic arrayer [35].  These arrays are used to quantify the relative gene expression in a 
set of samples.  Briefly, mRNA transcripts (target) from a pair of samples are reverse-
transcribed into cDNA and labeled with red and green fluorescent dyes.   
Labeled sample cDNA is hybridized to the array and the relative abundance of mRNA in
 
 
Figure 3: Two-color microarray experimental design 
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each sample can be inferred from the intensity of fluorescence in the red and green 
channels.  High-density oligonucleotide arrays, such as the Affymetrix platforms, have 
generally superseded two-color arrays.  Affymetrix arrays are single channel instruments, 
allowing for absolute quantification of expression [36].  With Affymetrix arrays, the 
abundance of target transcripts is related to intensity of fluorescent signal.  Affymetrix 
platforms use 25 mer oligonucleotide probes to quantify gene expression.  Multiple 
probes are targeted to specific sequences along the coding region of the genes represented 
on the array.  Probes are combined into probe sets consisting of between 11-20 probes in 
order to improve the sensitivity of the assay.  Mismatch probes, designed with one 
nucleotide base change from the perfect match probe, are intended to quantify the extent 
of non-specific hybridization.   
 
 
Figure 4: Probe sets on Affymetrix gene expression microarrays:  Probe pairs are 
designed to hybridize to different segments along the coding region of the target gene.  
Pairs consist of a perfect match and mismatch probe which differ at a single base pair.  
[36]. 
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In addition to gene expression platforms, Affymetrix has developed gene mapping arrays, 
capable of genotyping SNPs distributed evenly across the genome.  Gene mapping arrays 
incorporate 25 mer oligonuclotide perfect match and mismatch probes, similar to 
expression arrays.  Perfect match probes are designed to hybridize to one of two potential 
sequence variations, represented by a single base substitution at the middle of the probe 
sequence [37].  Probes are also included to match both the sense and complimentary anti-
sense DNA strands.  Genotype calls at each SNP location result from the detection of the 
presence or absence of the two associated signals.   
 
 
 
Figure 5: Fluorescent signal scanned from a gene mapping array: Rows two and 
three contain probes designed to hybridize to the A or B allele respectively.  A 
heterozygous individual is identified when both A and B signals are present. [36] 
 
 
A set of standards has been developed to promote the sharing of microarray data.  The 
Minimal Information About a Microarray (MIAME) recommendations stipulate that 
researchers should provide open access to information regarding the experimental  
protocols and analytical methods used, sample and array annotations, and both raw 
intensity and processed expression data [38].  Open access standards ensure that the 
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results derived from microarray analysis can be properly vetted by the scientific 
community and that the maximum benefit is gained from the data. 
 
 
2.6 Biological databases  
 
The rapid accumulation of biological knowledge has prompted the compilation of 
information into biological databases.  Databases maintained by the National Center for 
Biological Information and the European Bioinformatics Institute provide useful 
resources for biological and medical research.  Relevant gene information including the 
gene name, symbol, sequence, function and chromosomal location can all be found at 
these sources [39, 40].  Similar information on proteins is compiled [41].  Databases such 
as the Gene Expression Omnibus [42] and ArrayExpress [43] provide a repository for 
microarray expression datasets.  Other databases have been developed with the goal of 
categorizing genes and proteins into logical groups.  The Gene Ontology (GO) Database 
characterizes genes on the basis of three general categories: molecular function, cellular 
component and biological process [44].  Within each category, a nested vocabulary is 
established to classify genes with increasingly specific terms.  The Kyoto Encylopedia of 
Genes and Genomes (KEGG) Database groups genes and gene products according to 
canonical signaling and metabolic pathways [45].  KEGG also maintains graphical 
representations of pathways for visualization.  Compilation and logical organization of 
biological information in this manner facilitates biological research and accelerates the 
pace at which novel insights can be gained.
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Chapter 3: Microarray Pre-Processing and Analysis  
 
This chapter discusses methodologies for pre-processing and analysis of gene expression 
and gene mapping microarray data.  Pre-processing corrects for technical variation 
through background correction, normalization and summarization of probe-level 
measurements.  Analytical methods for microarray data identify differentially expressed 
genes, groups genes and samples according to common gene expression patterns, and 
detect gene expression patterns and gene sequence variations that are associated with 
phenotype.  
 
 
3.1 Pre-Processing  
 
Microarray technologies take advantage of the specific hybridization of oligonucleotides 
to complimentary sequences in order to quantify the abundance of specific transcripts or 
to characterize genetic variation at specific loci in the genome.  Expression measures or 
genotypes are derived from the processing of fluorescent signals.  In this process, there 
are many sources of obscuring variation, including non-specific hybridization, optical 
noise, reagent batch effects, microarray chip effects, and other stochastic differences in 
laboratory conditions [46].  Obscuring variation must be corrected before analysis so that 
the biological variation between the experimental conditions can be assessed.  Pre-
processing is used to correct for obscuring variation and derive adjusted expression 
values from the observed fluorescence intensity measures.  Pre-processing generally 
consists of three steps: background correction, normalization, and summarization [47].  
Background correction adjusts raw fluorescence intensities to remove signal originated 
from non-specific hybridization and optical noise.  Normalization modifies background-
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corrected intensity values to remove obscuring variation and scale values such that they 
are comparable across arrays.  Summarization is used to generate a single expression 
value for each probeset from the background-corrected, normalized intensity values of 
the constituent probes.         
 
 
3.1.1 MAS 5.0 pre-processing algorithm  
 
Affymetrix developed an algorithm (MAS5) for pre-processing gene expression arrays 
that treats each array separately[48].  The MAS5 background correction procedure 
calculates local background estimates across 16 rectangular regions of the chip mean as 
the lowest 2% of intensity values in each region.  Probe intensities are adjusted by 
subtracting a weighted average of the local background estimates.  Weights are 
dependent on the distance between the probe and the centroid of each region used for 
background estimation.  Following this step, non-specific hybridization is accounted for 
by subtracting the mismatch (MM) probe intensity from the perfect match (PM) probe 
intensity.  A separate procedure based on the average of MM and PM intensities is used 
to avoid negative values if MM is greater than PM.  For normalization, a single array is 
chosen as a reference to which all of the remaining arrays are normalized against.  A 
scale parameter is calculated by dividing the mean intensity of the reference array by the 
mean intensity of each non-reference array.  Non-reference arrays are normalized by 
multiplying the intensity values by the corresponding scale parameter.  The one-step 
Tukey’s biweight algorithm is used to generate expression values for each probeset.  In 
this process, summarized probeset expression values are obtained by a weighted average 
of probeset intensity values in which the weights are defined on the basis of the uniform 
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distance from the median intensity value.  Analysis of benchmark datasets in which 
specific transcripts are spiked-in at certain concentration has shown that MAS5 has 
slightly lower precision than other algorithms [47].   
 
3.1.2 Robust multi-array analysis pre-processing algorithm 
 
Model-based algorithms, such as robust multi-array analysis (RMA) [47], are an 
alternative to MAS5 that use information across arrays to account for obscuring variation.  
It should be noted that RMA ignores the MM intensity values.  Robust mutli-array 
analysis assumes that the observed fluorescent intensity consists of a normally distributed 
background component and an exponentially distributed signal component.  A 
background estimate for each array is obtained by fitting the parametric model to the 
intensity values.  Background is removed by subtracting the estimate from the perfect 
match intensity values.  Background corrected intensity values are normalized using 
quantile normalization [49].  In quantile normalization, intensity values in each array are 
sorted in increasing order.  Intensity values for each probeset are replaced by the average 
intensity values obtained by calculating the mean across arrays.  At last, each array is 
restored to its original order prior to sorting.  Application of quantile normalization 
results in equalization of the empirical distributions of each array.  In order to summarize 
probe-level measures into probeset expression measures, RMA fits the background 
corrected, normalized and log base 2 transformed probe intensities to a linear model [47].  
Model parameters are estimated using median polish to decrease the vulnerability to 
outliers.  Analysis of spike-in benchmark datasets has validated that RMA produces 
expression measures with high accuracy and precision [47].  
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3.1.3 Reference robust multi-array analysis  
 
Expression measures generated from multi-array pre-processing algorithms are highly 
dependent on the data used for normalization.  This becomes a problem when adding new 
samples to an analysis.  Reference RMA (RefRMA) [50] was developed to allow 
investigators to pre-process arrays using the same parameters generated from a reference 
dataset. Initially, RMA is run on a large, biologically diverse training dataset is to define 
a normalization vector through quantile normalization and a probe effect vector based on 
the probe affinities derived from the summarization step.  These vectors can be applied in 
the pre-processing of newly collected arrays to calculate probe set expression measures 
that are comparable to the training dataset.  Reference RMA can also be used to pre-
process large datasets at a lower computational cost than RMA.  
 
3.1.4 Bayesian robust linear model with mahalanobis distance algorithm for genotype 
calling 
 
Algorithms used for pre-processing gene mapping arrays use information across chips 
and SNPs to evaluate the presence or absence of signal and make genotype calls.  One 
such algorithm is the Bayesian robust linear model with Mahalanobis distance (B-
RLMM) [51].  Similar to expression analysis, the goal of pre-processing is to convert 
measured fluorescent intensity values into an estimated genotype while correcting for 
obscuring variation.  For each SNP represented on the array, summarization of probe 
intensity values results in two values, an A and a B signal, representing the two potential 
genetic variations.   Normalization and summarization processes are similar to those used 
in the RMA algorithm.  Briefly, probe intensity measures are quantile normalized, log 
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transformed and median polish is used to estimate probe affinity effects.  No background 
correction is necessary.  Genotype calls are made on the basis of the summarized A and B 
signals.  Transformations are used to represent the summarized signals in two-
dimensional space.  The contrast and size the signals are calculated as described below,  
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where SA and SB are equal to the A and B signals respectively.  In this transformed space, 
the three potential genotypes (ie. homozygous A, heterozygous or homozygous B) are 
grouped into three clusters.  A Bayesian procedure is used to define a unique set of 
clusters for each SNP.  Briefly, a subset of SNPs is selected to generate an initial guess of 
the cluster distributions (prior).  Next, signal values from each SNP are used to generate a 
specific estimate of cluster distributions.  This specific estimate and the generic prior are 
used to generate a posterior estimate of the cluster distributions.  Genotype calls are made 
by calculating the Mahalanobis distance between the transformed SNP signal values and 
the three clusters.  The genotype corresponds to the minimum of these distances.  Use of 
the B-RLMM algorithm produces a greater than 98% accurate call rate on reference 
samples derived from the HapMap project [51].   
 
3.2 Gene expression microarray analysis 
 
3.2.1 Differential expression analysis  
 
Identification of differentially expressed genes is a common goal in microarray analysis.  
Given microarray data from samples in a number of classes, differentially expressed  
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Figure 6: Genotype calling with B-RLMM – Genotypes represented as points in 
transformed space. Green points represent homozygous B genotypes, blue points 
represent heterozygous AB genotypes and red points represent homozygous A genotypes.  
 
 
genes are expressed at a high level in condition A and a low level in condition B or vice 
versa.  Initially, differentially expressed genes were identified using fold-change [52].  
However, fold-change is less than optimal because it neglects the variance in expression 
measures.  Statistical tests such as the Students t-test [53], anaylsis of variance (ANOVA) 
[54], or the Mann-Whitney test [55] have largely replaced fold-change in differential 
expression analysis.  Parametric tests use the class-specific mean and variance to evaluate 
whether there is enough evidence to reject the null hypothesis of no differential 
expression.  The Students t-test for example calculates a t-statistic as the difference in 
condition-specific means divided by an estimate of the pooled standard deviation [53].  
T-statistics much higher or lower than zero indicate differential expression.  A p-value 
can be calculated from the t-statistic to define the probability that the result could have 
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been obtained by chance.  Typically, p-values less than 0.05 indicate that the null 
hypothesis can be rejected.  In expression analysis, the p-value must be adjusted to take 
into account the number of hypotheses tested (e.g. 5% of ~20000 genes tested is ~1000 
false positive rejections of the null hypothesis).  Multiple testing procedures such as the 
Bonferonni correction  [56] or calculation of the false discovery rate [57] are used for this 
purpose.  The Bonferonni correction simply divides the original significance level by the 
number of genes tested [56].  This correction is highly conservative and often results in 
no differentially expressed genes.  The false discovery rate estimates the proportion of 
differentially expressed genes that are false positives [57].  An approximation of the false 
discovery rate can be obtained by permuting the class of the samples, calculating the test 
statistic and finding the number of genes that pass the significance threshold based on the 
permuted data [53].  Once a set of differentially expressed genes have been identified, 
new hypotheses regarding the active biological processes in each class of samples can be 
generated.  
 
 
3.2.2 Unsupervised classification  
 
Unsupervised classification methods utilize distance metrics to identify genes or samples 
with similar expression patterns.  A gene expression profile can be defined as the vector 
of gene expression values across all samples or the vector of expression for all genes in a 
given sample.  Genes with similar expression profiles tend to be co-regulated or involved 
in common cellular mechanisms [58].  With this observation, unsupervised classification 
methods have been used to infer the function of poorly characterized genes.  In cancer 
studies, samples with similar expression profiles tend to have similar clinical 
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characteristics.  Clustering has been used to define cancer subtypes for prognostic 
purposes and selection of therapeutic strategies [59, 60].    Hierarchical clustering is an 
example of an unsupervised classification method.  In hierarchical clustering, a nested 
tree-like structure is created by grouping the two most similar expression profiles in an 
iterative fashion [61].  Model-based clustering is an adaptation of unsupervised clustering 
methods that can be used to determine the confidence in cluster membership [62].  In 
model-based clustering, clusters are defined as multivariate normal distributions.  
Classification is based on fitting cluster-specific distributions to the data using either 
expectation maximization [63-65] or Bayesian methods [62, 66, 67].  Unsupervised 
classification methods are well suited for class-discovery in which the underlying 
structure of the dataset is unknown.  
 
 
3.2.3 Supervised classification  
 
Supervised classification methods use statistical hypothesis tests to identify significant 
genes and create a function capable of predicting the class of a new set of samples.  This 
concept is similar to machine learning and consists of three steps: feature selection, 
classifier specification and evaluation of the predictor on an independent set of samples.  
Golub et al. used supervised classification to classify leukemia samples into acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [59].  Genes 
associated with the ALL versus AML class distinction were identified using differential 
expression analysis.  Specifically, the signal to noise ratio defined as the difference 
between class-specific mean expression values over the sum of the standard deviation in 
expression values from each class.  A set of n genes with signal to noise ratios farthest 
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from zero were selected as informative genes for classification.  The number of genes 
parameter n was optimized using cross-validation on the training data.  Classification of 
test samples was based on a weighted voting scheme.  For each gene, the vote is 
calculated as the average expression value of the training samples subtracted from the 
expression value of the test sample.  The class of the test sample is calculated based on 
the linear combination of the votes of each gene weighted by the associated signal to 
noise ratio.  Classifiers are evaluated on an independent set of testing samples in which 
the classification is known.  It is important to maintain the independence of the training 
and testing data to avoid biasing the classifier [68].  Supervised classification methods 
have been used to classify cancer samples on the basis of biomarker expression, lymph 
node involvement and subtype [59, 68].  
 
3.2.4 Functional enrichment analysis 
 
Once an interesting gene set has been identified through differential expression analysis 
or other means, further analysis can be used to determine which cellular processes are 
over-represented.  Functional enrichment analysis compares the interesting gene set to a 
reference set of genes (ie. all genes represented on a microarray) [69].  Information from 
the Gene Ontology [44] or Kyoto Encyclopedia of Genes and Genomes [45] can be used 
to identify genes with common function.  The hypergeometric test can be used to assess 
the significance of enrichment.  Functional enrichment analysis can be used to infer 
which biological processes are activated or repressed by upregulation or downregulation 
of the genes in the interesting gene set.   
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3.3 Genotype analysis  
 
3.3.1  Linkage mapping  
 
Linkage analysis of genomic sequence data is used to identify genetic loci that are co-
transmitted more than expected by chance under independent inheritance [70].  Both 
parametric and model-free methods have been developed to assess linkage.  Parametric 
linkage analysis depends on the estimation of the recombination fraction, or the 
probability of recombination between two genetic loci, based on the observed genotype 
of related individuals.  The genetic model of disease, including the mode of inheritance, 
frequency of the disease allele and penetrance of the genotype, must also be defined [70].  
Linkage is determined by the calculation of a logarithm of the odds (LOD) score by a 
likelihood ratio test comparing the likelihood of linkage between a putative disease locus 
and a set of mapped marker loci against the null hypothesis of independent inheritance 
[70].  An LOD score greater than 3 indicates significant linkage.  Non-parametric 
methods operate independently of genetic models by comparing the number of shared 
alleles between affected sibling pairs with the expected value [70].  Analysis of the 
linkage between genetic markers has been used to map the relative location of markers or 
disease loci in the genome.   Linkage analysis is often used as a first pass to identify 
regions of interest for follow-up studies.        
 
3.3.2 Association studies  
 
Association testing of genomic data identifies alleles that contribute to disease 
susceptibility by comparing the frequency of occurrence in subjects with disease versus 
unaffected control individuals [71].  Simple association studies analyze the distribution of 
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alleles in case and control populations with 2 x 2 contingency tables.  Significance of 
association can be determined with the chi-square distribution [71].  The case-control 
study design may give false positive results in the presence of population stratification.  
Allele frequencies vary between different sub-populations according to genetic history.  
This issue can be avoided by stratifying the subject population on the basis of ethnicity.  
Methods have also been developed to estimate the population structure and adjust the test 
statistics appropriately [72, 73].  Alternatively, family-based association tests can be 
used.  Family-based association tests (FBATs) avoid the confounding effect of population 
structure by evaluating the test statistic within families [74].  The FBAT statistic 
compares the genotype of affected and unaffected offspring to the expected value derived 
from parental genotypes under a Mendelian inheritance model.  Signficance can be 
determined by comparing the magnitude of the test statistic against the normal 
distribution.  Due to linkage disequilibrium, associated markers are considered to be in 
close proximity to the susceptibility polymorphism.  In gene coding regions, analysis of 
the sequence and structure of homologous proteins can be used to differentiate between 
disease-related and disease-causing loci [75, 76].  
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Chapter 4: Prediction potential of candidate biomarker sets 
4.1  Summary  
This chapter discusses the identification and validation of candidate biomarker sets 
associated with molecular subtype and/or prognosis in multiple cancer types by the 
analysis of gene expression microarray data.  Independently derived expression profiles 
of the same biological condition often have few genes in common.  In this study, we 
created populations of expression profiles from publicly available microarray datasets of 
cancer (breast, lymphoma and renal) samples linked to clinical information with an 
iterative machine learning algorithm.  ROC curves were used to assess the accuracy of 
each profile for classification.  We compared the accuracy of profiles correlated with 
molecular phenotype against profiles correlated with relapse-free status.  In addition, 
profiles identified with supervised univariate feature selection algorithms were compared 
to profiles selected randomly from a) all genes on the microarray platform (random 
selection) and b) a list of known disease-related genes (a priori selection).  We also 
determined the relevance of expression profiles on test arrays from independent datasets, 
measured on either the same or different microarray platforms.  Highly discriminative 
expression profiles were produced on both simulated gene expression data and expression 
data from breast cancer and lymphoma datasets on the basis of ER and BCL-6 
expression, respectively.  Use of relapse-free status to identify profiles for prognosis 
prediction resulted in poorly discriminative expression profiles.  Supervised feature 
selection resulted in more accurate classifications than random or a priori selection, 
however, the difference in prediction error decreased as the number of features 
increased.  These results held when expression profiles were applied across datasets to 
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samples profiled on the same microarray platform.  Results suggest that many gene sets 
predict molecular phenotypes accurately.  Given this, expression profiles identified using 
different training datasets should be expected to show little agreement.  In addition, we 
demonstrate the difficulty in predicting relapse directly from microarray data using 
supervised machine learning approaches.   
 
4.2  Background 
Clinically validated biomarkers are highly valued in cancer pathology for diagnostic and 
prognostic purposes.  Biomarker sets are also used in clinical trials as early indicators of 
drug efficacy and toxicity.  Molecular profiling technologies have the potential to enable 
high-throughput candidate biomarker identification.  Use of oligonucleotide or spotted 
cDNA microarrays allows for the quantification of the mRNA concentration of thousands 
of gene products simultaneously.  Although measurement of the entire proteome is not 
yet possible, advances in mass spectrometry and chromatography provide similar 
capabilities at the protein level.  Molecular profiling approaches have been applied 
towards the study of chronic diseases, including muscular dystrophy [77], diabetes [78], 
arthritis [79], cardiovascular disease [80] and cancer [59, 81-84]. Microarray studies in 
which the class or phenotype (e.g. health vs. disease, responders vs. non-responders, etc.) 
of all samples is known can be used to identify discriminative features (i.e. gene 
expression profiles) that are statistically associated with class distinction [59, 82-84].  
These features can be used as potential biomarker sets to determine the phenotype of new 
samples and guide therapy appropriately. 
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Detection of candidate biomarkers from high-dimensional molecular datasets entails 
separation of signal from noise.  As such, techniques adapted from signal processing and 
machine learning can be applied.  The goal of machine learning is to reliably predict the 
class, or phenotype, of a new sample given only a set of measured input variables.  The 
definition of a function that equates input variables to response is called supervised 
learning. In general, supervised learning consists of three steps: feature selection, 
decision rule specification and estimation of generalization error [68].  Feature selection 
is the identification of informative features from noisy or uncorrelated features in the 
dataset.  Decision rule specification involves selection of a classification algorithm and 
definition of algorithm parameters by cross-validation [68, 85].  Feature selection and 
decision rule specification produce a classifier through the use of cross-validation on 
training data.  In this process, there is a risk of overfitting the training data, in which the 
classifier is trained to recognize noise and not class distinction.  The estimation of 
generalization error, or the misclassification rate expected when the classifier is applied 
to new samples, can be used to investigate the likelihood of overfitting.  An unbiased 
estimate of the generalization error can only be obtained from independent test data [68]. 
 
Feature selection is particularly important in gene expression profiling, in which the 
number of features (genes) is much larger than the number of observations (microarray 
data samples).  Identification of discriminative features eases the process of data 
interpretation and communication, decreases computation time for training, and, in 
biomarker identification, enables the development of reliable clinical assays.  Numerous 
feature selection algorithms can be found in the literature, most of which rank features in 
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a univariate manner, sorting them on the basis of correlation with class distinction [53, 
85, 86].  In molecular profiling studies, univariate methods are used more often than 
multivariate feature selection methods [87-89] due to their intrinsic simplicity and the 
higher computational cost of multivariate methods.   
 
Application of supervised feature selection methods in microarray analysis identifies a set 
of genes whose expression profiles are most correlated with response.  However, 
discriminative feature sets identified in multiple microarray studies of the same disease 
state or biological condition typically share few common genes [90-92], indicating 
perhaps that multiple gene subsets can be used as effective biomarker panels.  Many 
genes cluster into similar expression profiles and may have similar roles in signaling or 
metabolic pathways.  Variation between studies can also be partially attributed to 
biological variations between sample populations and technical variations, such as the 
microarray platform (cDNA vs. oligonucleotide), protocol and analytical techniques used 
[93, 94].  Moreover, selection of discriminative genes within a given dataset is dependent 
on the selection of training set arrays [90, 95-97].       
 
Given the presence of multiple, generally exclusive gene sets related to disease states 
such as metastatic breast cancer, it is appropriate to ask whether feature selection 
identifies gene expression profiles that classify better than is expected by chance, i.e. 
better than randomly selected gene sets.  It is also important to determine to what extent 
technical and biological variability between studies affects the generalization error of 
classifiers trained on expression profiles.  In this study, we analyzed a multitude of 
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publicly available microarray datasets consisting of expression data linked to clinical data 
for breast cancer, renal cancer, and lymphoma [60, 82, 98-102].  Decision rules, 
composed of features associated with response, were created using supervised, univariate 
feature selection algorithms [81, 85].  Our analysis considered multiple microarray 
technologies (Affymetrix, cDNA spotted arrays, cDNA oligonucleotide arrays), 
normalization, feature selection and classification methods.  Our results point to the 
efficiency of gene sets randomly selected from known disease-related genes in the 
accurate classification of cancer samples according to molecular phenotypes. Results also 
point to the challenges of predicting relapse directly from microarray data annotated with 
clinical outcome information.  
  
4.3  Materials and methods 
4.3.1  Microarray datasets 
Publicly available gene expression data for a multitude of cancer types (breast cancer, 
lymphoma, and renal cancer) was collected from the online repositories Gene Expression 
Omnibus (GEO) [42] and Stanford Microarray Database (SMD) [103] (Table 1). All 
datasets used in the study were linked to clinical data including outcome and were further 
restricted to exclude datasets with less than 100 samples.  Expression datasets analyzed in 
this article included data from multiple platforms (Affymetrix, cDNA, Hu25K), allowing 
us to assess the platform dependence of our results.  Typically, datasets were collected 
from population-based studies with no age/status restrictions.  Two exceptions to this rule 
are as follows: 1) dataset GSE2034 was restricted to breast cancer patients with lymph-  
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Table 1 - Description of microarray datasets used in biomarker set analysis 
Disease  
Type  Datasets Platform 
# of 
Arrays Restrictions Reference 
Breast 
Cancer 
GSE3494 HG-U133a 251 a Miller et al. [99] 
GSE2034 HG-U133a 286 b, c Wang et al. [101] 
NKI Hu25K 295 d, e, f Van de Vijver et al. [82] 
Sorlie cDNA 121 a Sorlie et al. [60] 
Diffuse 
large B-Cell 
Lymphoma 
Broad HG-U133a 176 a Monti et al. [100] 
GSE4475 HG-U133a 220 a Hummel et al. [98]  
Renal 
Carcinoma Zhao cDNA 177 a Zhao et al. [102]  
a. No restrictions 
b. Lymph-node negative 
c. No adjuvant therapy 
d. < 5 cm in diameter 
e. <= 52 years at diagnosis 
f. No previous history of cancer 
 
 
 
node negative disease and with no adjuvant therapy; and 2) dataset NKI  was restricted to 
patients with tumors less than 5 cm in diameter, and under age 52 at diagnosis (Table 1).   
 
Each microarray dataset was analyzed independently to evaluate the error in predicting 
relapse (or histological expression of a  surrogate biomarker of relapse) using univariate 
feature selection compared to the error from biomarker sets chosen randomly from either 
the entire set of genes represented on the microarray (random) or a smaller set of 
experimentally validated cancer-associated genes (a priori).  To this end, we used an 
iterative supervised, machine-learning approach, described below.  For completeness, we 
tested the dependence of our approach on the use of different pre-processing, feature 
selection and classification algorithms and cross-validation schemes.  The primary focus 
of our study was on breast cancer, where multiple datasets were available for analysis.  
Lymphoma and renal carcinoma datasets were used to assess the relevance of our 
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conclusions in other disease states.  All work described in this study was carried out using 
the R statistical environment [104] and was duplicated independently in Matlab unless 
otherwise noted. 
 
4.3.2  Pre-processing microarray data 
Microarray datasets were collected in raw format when available (GSE3494, GSE4475).  
Two pre-processing algorithms, Robust Multi-Array Analysis (RMA) [46] and MAS 5.0 
[48], were applied to these datasets to determine the effect of pre-processing on 
downstream analysis.  RMA was implemented with the Bioconductor package [105] in 
the R statistical environment [104].  MAS 5.0 was implemented with Array Express Lite.  
All other datasets were obtained in pre-processed form.  The methods used for pre-
processing in these cases are summarized briefly as follows.  The Broad and GSE2034 
datasets were pre-processed using MAS 5.0.  In the GSE2034 dataset, only chips with an 
average signal intensity of greater than 40 and a background signal of less than 100 were 
included and probe sets were scaled to a target intensity of 600 [101].  Sorlie and Zhao 
datasets were obtained from the Stanford Microarray Database (SMD) [103] in log base 2 
form.  Spots flagged by the scanning software were not included.  Missing values were 
imputed using a nearest neighbor algorithm [106].  Expression values in the NKI dataset 
were quantified by averaging the intensity across the Cy3 and Cy5 channels and 
subtracting a local background estimate [82].  Each channel was normalized to the mean 
intensity across genes. 
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4.3.3  Probe set annotation 
Probe sets on all platforms were annotated using gene identifiers maintained by the 
National Center for Biotechnology Information (NCBI).  Affymetrix probe sets were 
annotated using the hgu133a package in R.  Stanford clone identifiers were annotated 
using the SOURCE database [107].  Stanford cDNA datasets consisted of samples 
processed on different generations of cDNA platforms.  To obtain comparable data 
within each dataset, we limited the dataset to the clone identifiers represented on all 
generations.  This step resulted in 8404 and 39414 clone identifiers for the Sorlie and 
Zhao datasets respectively.    The NKI probe sets were annotated using Unigene cluster 
identifiers from Unigene build 158 [108].  Retired cluster identifiers were identified and 
re-annotated using records from Unigene.  These identifiers are sometimes split into 
multiple clusters.  In these cases, annotation was not possible.  These probe sets were 
excluded from the analysis.  By retaining only the probe sets that could be definitively 
annotated, we were left with 8069 probe sets in the NKI dataset for further analysis. 
 
4.3.4  Mapping between probe sets and genes  
A single probe set representing each gene was selected to correct for the varying 
redundancy of gene representation on microarray platforms.  In each platform considered 
in this study, approximately 60% of genes were represented by a single probe set.  Genes 
represented by multiple probe sets were dealt with in the following manner.  For 
Affymetrix datasets, probe set suffixes were used to remove redundant probe sets.  For 
the HG-U133a chip, probe sets are encoded with _at, _s_at and _x_at suffixes that 
describe the quality of probe design [109].  All _x_at probe sets (~10% of probe sets on 
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the array) were excluded.  For genes represented by an _at probe set and multiple _s_at 
probe sets, the _s_at probe sets were discarded.  Approximately 20% of redundant probe 
sets could be dealt with in this manner.  In cases in which a unique probe set could not be 
chosen by the suffix, the average expression value of the remaining probe sets was used.  
For the non-Affymetrix probe sets, a unique probe set was chosen by selecting the probe 
set with the highest variance across samples. 
 
4.3.5  Feature selection 
Microarray datasets were iteratively divided into learning sets (LS) and test sets (TS) to 
create a population of classifiers and determine their classification performance in a 
Monte Carlo cross-validation approach [110].  Two types of response variables were used 
to divide samples into groups of poor prognosis and good prognosis, either histological 
expression of biomarkers (ER status in breast cancer, BCL-6 status in lymphoma) or 
relapse-free survival, in which relapse is defined as disease recurrence or death from 
disease.  Learning sets and test sets were selected by first dividing datasets by response 
variable and then randomly selecting equal proportions of arrays from each class.  Two 
different partitions were used: 2/3 LS, 1/3 TS and 1/2 LS, 1/2 TS.  Learning sets were 
used to select informative features and train the decision rule.  Genes were selected from 
the LS in a supervised manner using a univariate feature selection algorithm [85].  
Briefly, each gene was ranked by the ratio of between class sum of squares to within 
class sum of squares.  High scoring genes have large between class variances and small 
within class variances and are therefore correlated with class distinction.  A second 
method was used to determine if our results were sensitive to feature selection algorithms 
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[81].   In this second method, genes are ranked by the signal to noise ratio, namely the 
ratio of the difference in class-specific  means  to  the  sum  of  the  class-specific  
standard  deviations  [81].  This is quite similar to the two-sample t-statistic.  We use the 
term signal to noise ratio to maintain consistency with previous literature in the field.  For 
comparison, genes were selected randomly from either the entire list of genes represented 
on the array (random), or a list of experimentally validated disease-related genes obtained 
from the Ingenuity Pathways Database [111] (a priori). All three feature sets (feature 
selected, a priori, and random) were used in downstream analyses. 
 
4.3.6  Classification 
Two classification algorithms, diagonal linear discriminant analysis (DLDA) and k- 
nearest neighbour (NN, k = 3), were used to generate decision rules on the basis of the LS 
data.  The NN algorithm classifies test samples according to the class of the three closest 
samples in the training set using Euclidean distance [85].  DLDA is based on the 
maximum likelihood discriminant rule [85].  These relatively simple classifiers have been 
shown to give accurate classifications in the analysis of expression data and appear to 
perform as well as or better then more sophisticated algorithms, such as support vector 
machines, and resampling methods, such as bagging or boosting [85, 86]. 
 
4.3.7  Validation 
To obtain an estimate of generalization error, decision rules were applied to 
the corresponding TS.  The confidence (δ) with which each sample was classified was 
calculated as follows:  
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in which dR and dN are distances measured between the test sample and the centroid of the 
poor and good prognosis LS, respectively.  Samples are classified as good prognosis if 
the score is greater than 0.5 and vice-versa.       
 
With this methodology, the classification performance of the decision rules could be 
visualized and compared with the use of receiver operating characteristic (ROC) curves 
[112].  ROC curves plot sensitivity, or detection rate, (β) against 1-specificity, or false 
alarm rate (α). 
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Classification performance was determined from the area under the curve (AUC).  
Accurate classifiers have high sensitivity across the range of specificity and therefore 
have a large AUC.  ROC curves were generated for each classifier using the ROC 
package in R.  The score δ was divided into thresholds and β and α were calculated at 
each cut-off point.  The AUC of each classifier was then calculated using the sum of 
trapezoids method.  The entire process of feature selection, decision rule specification 
and estimation of generalization error was repeated 100 times to determine the expected 
performance of each gene set on a randomly selected set of samples.  Average ROC 
curves were calculated from the distribution of detection rates at given false alarm rates 
[113].  Empirical confidence intervals were obtained as the 97.5% and 2.5% quantiles of 
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this distribution.  The expected classification performance was quantified using a 
prediction error metric E defined as 1-AUC.  A smaller E value corresponds to a more 
accurate classifier. 
 
4.3.8  Simulated expression data 
Simulated microarray datasets were generated to verify that the machine learning 
algorithm described above leads to accurate classification of well-separated data.  
Simulated expression data was created in the manner described by Bura and Pfeiffer 
[114].  Datasets consisted of 100 observations with 1000 variables each, corresponding to 
arrays and genes respectively.  Half of the observations were labeled as class 1 and the 
remainder were labeled class 0.  All data for class 0 samples were drawn from a 
multivariate normal distribution with mean 0 and a covariance matrix of Σ.  Five percent 
of genes were simulated to be differentially expressed.  For class 1 samples, differentially 
expressed genes were drawn from a mixture of two multivariate normal distributions with 
means 0 and 2 and covariance structure Σ.  The mixing probability was 1/2.  Non-
differentially expressed genes were generated from the same distribution as class 0 
samples.  The covariance matrix Σ = σij was generated with a block structure with σij = 
0.2 for | j-i | ≤ 5 and 0 otherwise to model gene co-regulation. 
 
4.3.9  Statistical significance of molecula profile prediction 
To determine the significance of the calculated prediction error metric E for molecular 
profile prediction in breast cancer and lymphoma, the machine learning algorithm was 
repeated 1000 times with permuted class labels.  An empirical p-value was calculated as 
  
40 
the fraction of decision rules based on permuted class labels that performed better than 
the expected classification performance, E (described above),  of decision rules based on 
true class labels.  Permutation processes give an estimate of the likelihood that the true E 
value could be obtained by chance alone and are frequently used in similar studies for 
this purpose [53, 115]. 
 
4.3.10  Independent validation 
In addition to cross-validated generalization error, we determined the classification 
accuracy across datasets.  To this end, decision rules trained on one dataset were tested in 
both the corresponding test subset and datasets obtained by other laboratories.  For across 
platform comparisons (Affymetrix vs. Hu25K, Affymetrix vs. cDNA), probe sets were 
matched by annotation to Entrez Gene identifiers. 
 
4.4  Results and Discussion  
4.4.1  Simulated datasets confirm the performance of classification algorithms 
Analysis of simulated gene expression datasets indicated the effectiveness of the feature 
selection and classification algorithms used in this study to predict binary endpoints.  
Simulated datasets consisting of 100 observations and 1000 features were designed to 
approximate a binary classification problem [114].  Expression values were drawn from a 
multivariate normal distribution with mean equal to 0.  Differentially expressed genes 
were simulated from a mixture of the original distribution with a second multivariate 
normal distribution with mean equal to 2.  Our computations, presented in Figure 7, 
produced highly discriminative decision rules on simulated expression data.  Elimination 
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of differential expression, simulated by generating all values from the same distribution, 
resulted in classifiers with poor classification performance.  This indicates that our 
algorithm accurately classifies well-separated data and avoids over-fitting the training 
data (Figure 7).  
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Figure 7 - Classification of Simulated Gene Expression Data. Receiver operating 
characteristic (ROC) curves showing classification performance of DLDA classifiers on 
simulated gene expression data.  The symbols α and β are 1-specificity and sensitivity as 
described in the Methods section.  Solid lines are average ROC curves over 100 iterations 
of training and test set selection.  Dashed lines are empirical 95% confidence intervals.  
Bar plots give the mean 1-AUC (E) with error bars showing empirical 95% CIs.   
 
 
 
4.4.2  Univariate feature selection is a poor predictor of relapse in breast, lymphoma 
and renal cancers 
 
Computations on breast cancer microarray datasets from four independent cohorts of 
patients (GSE3494, GSE2034, NKI, Sorlie; Table 1) indicate the poor potential of 
univariate feature selection in predicting relapse-free survival.  Figure 8 shows the 
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classification error metric E (described in the methods section) as a function of the 
number of features used for classification. Columns 1 and 2 in this figure correspond to 
classification with respect to ER-status and relapse-free survival, respectively. Dark gray  
bars indicate univariate feature selection whereas light and medium gray bars correspond, 
respectively, to random selection from either the entire gene set or from an a priori gene  
set. Error bars indicate the variance over one hundred iterations of the machine learning 
algorithm.  As the figure shows, decision rules trained on relapse-free status classify test 
samples with low accuracy. Analysis of diffuse large B-cell lymphoma (DLBCL) and 
conventional renal cell carcinoma (CRCC) datasets similarly yielded high errors in the 
prediction of relapse-free status (Figure 9).  Survival time is a multi-factorial response 
variable with many potential confounding factors (e.g. lifestyle, age, etc.) that may affect 
gene expression.  The influence of these confounding factors may result in tumor classes 
that are highly heterogeneous in regards to gene expression.  These results indicate the 
difficulty in predicting relapse-free status in several forms of cancer from microarray data 
with the use of univariate feature selection. 
 
3.4.3  Univariate feature selection as well as randomly chosen features from a priori 
knowledge set classifies microarray data according to molecular phenotype 
 
In contrast, machine learning methods classified microarray datasets according to 
molecular phenotype with high accuracy (Figure 8).  In analysis of breast cancer datasets, 
Figure 8 shows that decision rules trained on ER status classified test samples more 
accurately than decision rules trained on relapse-free status. These results agree with 
previous studies in that the expression profiles of many genes seem to be correlated with 
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Figure 8 - Prediction error of DLDA classifiers trained and validated on breast 
cancer datasets.  Column 1: Classifiers trained on ER-status.  Column 2: Classifiers 
trained on relapse-free status.  E is the mean 1-AUC of the corresponding set of ROC 
curves, calculated as described in the Methods section.  Error bars show empirical 95% 
CIs. 
 
 
 
ER status [83, 116].  Estrogen receptor is a hormone-activated transcription factor [117] 
and also participates in cellular signaling by heterodimerization with membrane-bound 
receptors such as the endothelial growth factor receptor [117].  Loss of estrogen receptor 
expression inhibits ER-responsive gene transcription and signaling in downstream 
pathways and therefore can be expected to affect the expression of downstream genes in a 
similar manner across tumors.  Consistent with the analysis of breast cancer data, 
lymphoma datasets exhibited low errors in the prediction of BCL-6 status.  BCL-6 is a 
zinc-finger protein that functions as a transcriptional repressor [118] and is expressed in 
germinal center B cells [119].  In DLBCL, BCL-6 expression, assessed by both 
immunohistochemistry and RT-PCR, has been associated with better survival in several 
studies [120, 121].  Univariate feature selection may be successful in predicting 
molecular phenotype due to the fact that expression profiles of many genes are correlated 
with changes in expression of these transcriptional modulators. 
 
To determine whether gene sets identified with supervised feature selection are uniquely 
correlated with response, decision rules were generated both with and without supervised 
feature selection.  In the absence of supervised feature selection, gene sets were drawn 
randomly from either the entire genechip (random selection) or a list of known disease-
related genes (a priori selection)) (Figure 8).  Random selection of subsets of n genes 
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Figure 9 - Prediction error of DLDA classifiers trained and validated on diffuse 
large B-cell lymphoma and conventional renal cell carcinoma datasets.  Column 1: 
Classifiers trained on BCL-6 status.  Column 2: Classifiers trained on relapse-free status. 
Row 1: Diffuse large B-cell lymphoma.  Row 2: Conventional renal cell carcinoma.  E is 
the mean 1-AUC of the corresponding set of ROC curves, calculated as described in the 
Methods section. Error bars show empirical 95% CIs.  
 
 
 
gives a baseline error rate expected for classification based on decision rules with n 
features.  A priori selection provides a baseline error rate based on the known pathology.  
In Figure 2, we demonstrate that decision rules that incorporate supervised feature 
selection classify test samples more accurately than decision rules using a priori selection 
or random selection.  However, in molecular phenotype prediction, the difference in 
prediction error decreases drastically as the number of features increases.  This indicates 
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that the power of univariate supervised feature selection methods lies in identifying small 
sets of discriminative features.   
 
Exclusivity of predictive genesets has been demonstrated previously by investigating the 
classification potential of feature sets found down the list of genes ranked by their 
association with response [90].  Consistent with these previous observations, we 
demonstrate that randomly selected gene subsets classify molecular phenotype much 
better than the 50% error rate expected from random classification.  In addition, limiting 
the feature space to genes that have demonstrated disease-relevance in the experimental 
setting improves classification performance of randomly selected gene sets.  These results 
suggest that the presence of multiple, mostly exclusive biomarker sets identified from 
different studies [82, 83, 99, 101] can be partially attributed to the large number of 
combinations of discriminative feature sets [96]. 
 
4.4.4  Error in predicting relapse is insensitive to normalization and classification 
algorithms  
 
Our computations indicate that classification error is only weakly dependent on 
normalization, feature selection, classification and training/testing partition.  Breast 
cancer dataset GSE3494 was used to assess the effects of these classification parameters 
on predicted error.  Results depicted in Figure 10 demonstrate that these parameters have 
little effect on the prediction of relapse-free survival, whereas pre-processing 
methodologies may have a small impact on the prediction error of ER status. 
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Figure 10 - Senstivity of classifiers to normalization and machine-learning 
parameters. Decision rules trained and validated on breast cancer dataset GSE3494 
using supervised feature selection. Row 1: Expression values obtained using different 
pre-processing algorithms.  Row 2: Different univariate feature selection methods. Row 
3: Different classification schemes. Row 4: Different mode of partition into training and 
test data.  E is the mean 1-AUC for the corresponding set of ROC curves, calculated as 
described in the Methods section.  Error bars are empirical 95% CIs. 
 
 
 
4.4.5  Leave-one-out cross-validation scheme may lead to overfitting 
 
It has been shown that decision rules based on microarray data are capable of clearly 
differentiating tumors by outcome when all data is used for feature selection in a leave- 
one-out cross-validation scheme.  Our findings validate previous results in the literature 
concerning, for example, the prediction of relapse in lymphoma [81].  In their study, 
Shipp et al. [81] used a machine learning procedure consisting of feature selection with 
the signal to noise ratio, classification by a weighted-voting scheme and leave one out 
cross-validation on a cohort of 58 lymphoma patients linked to clinical outcome.  
Importantly, the final geneset was selected from the consensus of all 58 leave-one out 
models of the data.   Using Kaplan Meier analysis [122], Shipp et al. demonstrated a 
significant difference in survival between the classes predicted by machine learning.  We 
replicated their calculations in this study using a larger microarray dataset (GSE4475, 
Table 1) and found similar results using both their and our methods of feature selection 
and classification (Figure 11, Row 1). Next, we divided the data in GSE4475 into a 
learning set (randomly selected set of 58 arrays) and test set (remaining 101 arrays) and 
computed Kaplan Meier survival curves.  Results shown in row 2 of Figure 11 
demonstrate the diminished capacity to identify groups of tumors with different survival 
rates when complete separation of training and testing sets is maintained in the    
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Figure 11 - Kaplan-Meier plots of survival rates for predicted tumor classes with 
different feature selection/cross-validation methods. Classifiers trained on the basis of 
relapse-free status on diffuse large B-cell lymphoma dataset GSE4475.  Column 1: Signal 
to noise ratio.  Column 2: Ratio of between class to within class sum of squares.  Row 1: 
Leave-one out cross-validation.  All data used for training and testing.  Row 2: Training 
and test sets selected randomly from the dataset.  Training based on leave-one out cross-
validation.    
 
 
computations.  If feature selection is included in the cross-validation procedure, such that 
features selected only from training data were applied to the test data, the difference in 
survival time between predicted classes decreases.  These results suggest the possibility 
  
50 
of overfitting in previously reported classifiers based on microarray data linked to clinical 
microarray data linked to clinical outcome. 
 
4.4.6  Molecular phenotype prediction is maintained in across dataset cross-validation 
on the same microarray platform 
 
Next, we tested whether prediction error calculated by within dataset cross-validation 
holds when decision rules trained on one dataset are applied to arrays from other datasets 
profiling similar populations. Within dataset cross-validation may be biased according to  
the degree of non-specific correlation between the training and test data.  Non-specific 
correlation can be described as technical noise that arises in sample preparation, 
hybridization and scanning and results in higher correlation between data collected from 
the same lab compared to data collected in different labs [93].  To investigate this issue 
further, we used the Affymetrix dataset GSE3494 for developing decision rules for ER 
status prediction and applied these rules  to arrays profiled on either the same (GSE2034) 
or different microarray platforms (NKI and Sorlie). There was no need to validate relapse 
prediction across datasets since our results showed poor prediction capacity even for 
within dataset cross-validation. Figure 12 illustrates the results of this analysis in the form 
of ellipses whose size and shape indicate the distribution of prediction errors. The column 
on the left (Column 1) corresponds to computations using univariate feature selection and 
the column on the right (Column 2) indicates results corresponding to random selection 
from an a priori dataset. The figure shows that the prediction error and its variance were 
much lower on test datasets profiled on the same platform (Figure 12, Row 1) in 
comparison to test datasets using different platforms (Figure 6, Rows 2 and 3).  The same 
trend held true when the decision rule was based on feature selection from a random set 
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Figure 6. Prediction error of DLDA classifiers on breast cancer datasets by within-
dataset and across-dataset cross-validation. Decision rules trained on ER-status.  
Ellipses are centered on the mean 1-AUC of the associated ROC curves.  The major axis 
points in the direction of maximum variance.  Lengths of the major and minor axes are 
proportional to the standard deviation of the data in each direction.  Column 1: Prediction 
error of decision rules based on univariate ranking.  Column 2: Prediction error of 
decision rules based on random selection of features from a subset with a priori disease 
relevance.   = 5 features/set,  = 10 features/set,  = 20 features/set,  = 40 
features/set.
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chosen with a priori knowledge (Figure 6, Column 2).  These results suggest that decision 
rules obtained for classification do not accurately predict molecular phenotype in 
microarray data obtained using different platforms, possibly due to different strategies in 
probe design, or shortcomings in the matching of probes using probe set annotations 
[123]. Overall, these results demonstrate that bias resulting from non-specific correlation 
is negligible when samples are analyzed on the same platform. Results also validate the 
use of feature selection algorithms to identify small, discriminative feature sets that can 
be adapted for use in biomarker panels for identifying molecular phenotypes. 
 
4.5  Conclusions 
Biomarker sets derived from different gene expression microarray datasets for the 
purpose of predicting molecular phenotype or relapse in cancer contain very few common 
genes [91, 92]. In a typical microarray experiment, expression values of many genes are 
correlated with response [95, 96] and therefore, one could assume that multiple 
biomarker sets may accurately predict the classification of arrays into defined 
phenotypes. In this study, we used an iterative machine learning approach to determine 
the prediction potential of biomarker sets chosen using univariate feature selection from 
training sets selected randomly.  On simulated gene expression data, this approach 
generated several highly discriminative decision rules.  Similarly, multiple expression 
profiles capable of classifying tumors by molecular phenotype were identified in both 
breast cancer and DLBCL datasets.   
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We also compared the prediction error resulting from supervised feature selection vs. 
features selected randomly from either the entire set of genes represented on the 
microarray or an a priori defined subset of disease-relevant genes.  Overall, univariate 
feature selection led to more accurate classification; however, the difference in prediction 
errors decreased as the number of features increased.  Similar results were also observed 
in the application of decision rules to samples from other gene expression datasets 
profiled on the same microarray platform. From this, we conclude that the presence of 
multiple biomarker sets in the prediction of molecular phenotype arises from the large 
number of genes correlated with response.   
 
In contrast, decision rules trained on the basis of relapse-free status classified samples 
with relatively high prediction errors in breast cancer, DLBCL and CRCC datasets.  
Specifically, prediction error was approximately 40% in all cases that were studied 
regardless of the method used for feature selection.   Overall, these results indicate the 
difficulty of developing biomarker sets predictive of cancer relapse using a single 
microarray dataset. Our results do not apply to meta-analytical approaches, in which 
cancer relapse predictions are obtained by integrating data from multiple microarray 
datasets prior to machine learning [124-126]. In addition, combined use of clinical 
information and gene expression data may result in decision rules with better accuracy in 
predicting relapse [127-129].
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Chapter 5: Expression profiles of switch-like genes in classification of tissue types 
and infectious disease 
 
5.1  Summary 
 
This chapter describes classification of tissue type and infectious disease phenotypes on 
the basis of the expression of bimodal, or switch-like, genes.  Compilation of gene 
expression microarray datasets across diverse biological phenotypes has led to the 
identification and annotation of genes with bimodal expression patterns in the mouse and 
human genome.  Approximately fifteen percent of known human genes exhibit switch-
like expression profiles.  Additionally, the switch-like gene set is enriched with genes 
expressed in the extracellular space and cell membrane.  Evaluation of switch-like genes 
in large-scale microarray datasets may provide further insight into the biological 
relevance of bimodal gene expression patterns.  In addition, it is of interest to determine 
the potential of bimodal genes for class discovery and class prediction.  Use of a model-
based clustering algorithm accurately classified more than four hundred microarray 
samples into nineteen different tissue types on the basis of bimodal gene expression.  The 
algorithm demonstrated similar accuracy in the classification of microarray data 
corresponding to hepatitis C, influenza, HIV-1 and malaria infection.  Classification 
accuracy was exceptional even with class-specific sample sizes between ten and twenty 
arrays.  A supervised classification algorithm, in which feature selection was restricted to 
switch-like genes, also recognized tissue-specific and infectious disease specific 
expression profiles in independent test datasets reserved for validation.  Classification of 
simulated microarray data indicated the validity of our observations in a large number of 
circumstances.  Moreover, determination of consistent “on” and “off” states of switch-
like genes in various tissues and diseases allow for the identification of 
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activated/deactivated genes and pathways.  Functional enrichment analysis demonstrated 
that activated switch-like genes in neural, skeletal muscle and cardiac muscle tissue tend 
to have tissue-specific roles.  A majority of activated genes in infectious disease are 
involved in processes related to the immune response.  Our results indicate that switch-
like gene sets capture genome-wide signatures from microarray data in health and 
infectious disease.  Furthermore, we provide evidence that bimodal genes are involved in 
temporally and spatially active mechanisms including tissue-specific functions and 
response of the immune system to invading pathogens. 
 
5.2  Background 
Gene expression is controlled over a wide range at the transcript level through complex 
interplay between epigenetic modifications, DNA regulatory proteins, and microRNA 
molecules [14, 130, 131].  Genome-wide screening of expression profiles has provided an 
expansive perspective on gene regulation in health and disease. Identification of 
constitutively expressed housekeeping genes has aided in the inference of sets of minimal 
processes required for basic cellular function [132, 133].  Similarly, we have identified 
and annotated genes with switch-like expression profiles at the transcript level in the 
mouse and human, using large microarray datasets of healthy tissue [134].    Genes with 
switch-like expression profiles represent fifteen percent of the human gene population.  
Classification of samples on the basis of bimodal or switch-like gene expression may 
give insight into temporally and spatially active mechanisms that contribute to 
phenotypic diversity.   Given the variable expression of switch-like genes, they may also 
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provide a good candidate gene set for the identification of clinically relevant expression 
signatures. 
 
The high-dimensionality inherent in genome-wide quantification makes extracting 
meaningful biological information from gene expression datasets a difficult task.   Early 
attempts at genome-wide expression analysis used unsupervised clustering methods to 
identify groups of genes or conditions with similar expression profiles [61, 135, 136].   
Biological insight can be derived from the observation that functionally related or co-
regulated genes often cluster together.   Supervised classification methods require 
datasets in which the class of the samples is known in advance.  Statistical hypothesis 
testing [53, 92] is used to identify groups of genes that exhibit changes in expression 
associated with class distinction.  Significant genes can be used to build decision rules to 
predict the class of unseen samples [83, 84, 101].  Unsupervised classification is better 
suited for class discovery whereas supervised classification is tailored for class 
prediction.  In both of these complimentary approaches, dimension reduction can lead to 
increased classification accuracy. 
 
Many simple unsupervised learning algorithms rely on distance metrics to either partition 
profiles into distinct groups [137, 138] or build clusters from pair-wise distances in a 
nested, hierarchical fashion [61].  The optimal number of clusters must be defined 
heuristically or in advance and confidence in cluster membership is difficult to 
determine.  Model-based clustering provides the necessary statistical framework to 
address these concerns while allowing for class discovery.  In model-based clustering, it 
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is assumed that similar expression profiles are generated as draws from a set of 
multivariate Gaussian random variables.  Clusters are identified by fitting the parameters 
of the cluster-specific distributions to the data.  Expectation-maximization [63-65] or 
Bayesian methods [66, 67, 139] are used for optimization. Estimation of the number of 
clusters as well as the incorporation of confidence in cluster membership is implicit in 
this process. 
 
Methods such as unsupervised, supervised and model-based classification provide the 
means to evaluate switch-like gene expression patterns in high-dimensional datasets 
profiling diverse biological conditions.  In this study, we used these methods to identify 
tissue and disease specific expression signatures composed of switch-like genes.  For this 
purpose, we compiled two large-scale gene expression microarray datasets from publicly 
available resources.   The first dataset included samples spanning nineteen different tissue 
types from healthy donors.  The second dataset included samples from donors with one of 
a number of infectious diseases (HIV infection, hepatitis C, influenza, and malaria).   Our 
results demonstrate that bimodal gene expression profiles provide tissue-specific 
identification of samples in a dataset of healthy tissues.  In addition, classification of 
switch-like expression patterns identifies infectious disease types with high accuracy and 
further specifies the tissue from which the diseased sample was obtained. Moreover, the 
set of activated switch-like genes for various disease and tissue types provide biologically 
significant information about the molecular basis of phenotype distinction.  
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5.3  Materials and methods 
5.3.1  Microarray Datasets 
 
Microarray datasets used in this study were compiled from online public repositories, the 
Gene Expression Omnibus (GEO) [42] and the Array Express (AE) [43].  All datasets 
were profiled on the HGU133A or its recently expanded version, the HGU133plus2 
platform.  The datasets used in the study are shown in Table 2.   
 
5.3.2  Normalization 
 
Prior to normalization, datasets were filtered such that only the 22,277 probe sets 
common to both the HGU133A and HGU133plus2 platforms were retained.  Reference 
robust multi-chip averaging (refRMA) [50] was used for normalization.   RefRMA is an 
adaptation of the classic RMA approach [47] that is better suited for large datasets.  
Briefly, RMA background adjustment was applied to each array.  Arrays were 
normalized by fitting probe level intensities for each chip to an empirical distribution 
obtained by applying quantile normalization to an 800-array training set [134].  Probe 
affinity effects were estimated by median polishing on the training set and used to adjust 
the normalized probe level measures.  Following these steps, probe set expression values 
were derived from the median value of constituent probe level intensities.  
 
5.3.3  Probeset Annotation 
Probe sets were annotated using entrez gene ID, emsembl accession number, gene 
symbol, Gene Ontology terms [44] and KEGG pathways [45].  Gene identifiers and gene 
ontology terms were obtained from the HGU133plus2 annotation information on the 
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Table 2 – Microarray datasets used in the analysis of bimodal expression patterns 
Tissue Phenotype Data 
Tissue  No. of Samples Gene Expression Omnibus/Array Express Accn. # 
Adipose 10 GSE3526 
Adrenal 20 GSE3526, GSE8514, GSE2316 
Brain 89 GSE3526, GSE7621, GSE7307, GSE2361, E_AFMX-11, 
E-TABM-20,  
Colon 10 E-TABM-176, GSE8671, GSE9254, GSE9452 
Epidermal 25 GSE1133, GSE2361, GSE3419, GSE3526, GSE7307 
Heart 38 E_AFMX-11, E-MIMR-27, GSE1133, GSE2240, 
GSE2361, GSE3526, GSE3585, GSE7307 
Kidney 10 E_AFMX-11, GSE2004, GSE2361, GSE3526, GSE7392 
Liver 10 E_AFMX-11, GSE2004, GSE3526, GSE6764 
Lung  26 E-MEXP-231, GSE10072, GSE1133, GSE2361, 
GSE3526 
Mammary 15 E-TABM-66, GSE2361, GSE3526, GSE7307, GSE7904  
Muscle  64 GSE10760, GSE2328, GSE3526, GSE5110, GSE6798, 
GSE7307, GSE9103,  
Ovary  10 GSE2361, GSE3526, GSE6008, GSE7307 
Pancreas  6 GSE1133, GSE2361, GSE7307 
Peripheral 
blood 
12 GSE7462, GSE8608, GSE8668, GSE8762,GSE9692 
Small 
intestine 
7 GSE2361, GSE7307 
Spleen 12 GSE2004, GSE2361, GSE3526, GSE7307 
Stomach 10 GSE2361, GSE3526, GSE7307 
Testis 38 E_AFMX-11, GSE1133, GSE2361, GSE3218, GSE3526, 
GSE7307, GSE7808 
Thymus  5 GSE1133, GSE2361, GSE7307  
 
Infectious Disease  
Disease  No. of Samples Gene Expression Omnibus/Array Express Accn. # 
Hepititis C 147 GSE11190, GSE7123 
HIV 41 GSE6740, GSE9927 
Influenza A  28 GSE6269 
Malaria 15 GSE5418 
 
 
 
Affymetrix website in March 2008.  KEGG pathway annotations were obtained from the 
KEGG ftp site on April 28th, 2008. 
 
5.3.4  Identification of bimodal genes 
Bimodal genes were identified in expression data of healthy tissues [134] using a 
statistical method previously applied to detecting bimodality in blood glucose 
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concentrations [140, 141].  For each gene, we tested the alternative hypothesis that the 
expression distribution fits a two-component Gaussian mixture model versus the null 
hypothesis that expression follows a single normal distribution. Identification of 
bimodality can be confounded in the presence of skew normal distributions.  To correct 
for skewness, expression values were adjusted using the box-cox transformation 
[142].  Parameters of the two-component mixture model were fit using expectation 
maximization [143].  Parameters of the single normal distribution were estimated from 
gene-specific sample means and standard deviations.  The log-likelihood ratio test 
statistic -2logλ was used to reject the null hypothesis.  P-values were generated by 
evaluating the chi-square distribution with six degrees of freedom at the values of the test 
statistic.  Genes with p-values less than 0.001 were selected as candidate bimodal genes.  
This subset of genes was further reduced by restricting the standardized area of 
intersection between the distributions of the component Gaussians [144].  We evaluated 
several increasingly stringent restrictions on the standardized area of intersection (<=0.1 
and <=0.01).  These thresholds produced sets of 1265 and 293 bimodal genes, 
respectively. 
 
5.3.5  Identification of "on" genes in brain, skeletal muscle, cardiac muscle, lung 
and infectious disease phenotypes 
 
Bimodal gene expression values were binarized by defining a gene-specific threshold at 
the intersection of the probability density functions of the two-component mixture 
models [144]. Expression values above this threshold are described as "high" or "on". 
Bimodal genes in the "on" state were identified using the Bernoulli process  [144]. 
Briefly, each observation or sample was modeled as an independent trial.  Success was 
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defined as expression in the "on" mode.  P-values were calculated from the binomial 
distribution with an equal probability of success and failure.  A value of p<=0.01 
indicates a significant association between bimodal gene expression and phenotype.   
 
5.3.6  Functional Enrichment 
 
Gene sets characterized by KEGG pathways and GO terms were analyzed to identify 
functional categories enriched with sets of bimodal genes biased to the "on" or "off" 
mode in healthy and disease phenotypes.  We assessed the enrichment of functional gene 
sets by comparing the number of “on” or “off” genes observed in a particular functional 
group to the number expected by chance [69].  The hypergeometric test was used to 
assign significance to the enriched functional gene sets.  P-values less than 0.001 were 
considered significant.   
 
5.3.7  Distance-based clustering 
 
Distance-based clustering algorithms implemented in the R statistical environment were 
used to classify tissue samples into groups with similar expression of bimodal genes.  For 
completeness, we used both Kmeans and hierarchical clustering algorithms with 
Euclidean distance as a distance metric.  Given a set of n observations defined in p-
dimensional space (p = number of genes), the Kmeans algorithm partitions observations 
into K clusters by iteratively minimizing an objective function associated with cluster 
membership [145].  In our implementation, we ran Kmeans for ten iterations with ten 
different initial cluster centroid locations and retained the cluster partition associated with 
the minimal within-cluster sum of squares. Hierarchical clustering builds a dendrogram 
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from the pair-wise distance between observations.  We used complete linkage to define 
the distance between clusters and observations.  A single cluster solution was obtained 
from the dendrogram by cutting the tree at a level which produced the desired number of 
clusters.   In both of these algorithms, the data-driven optimal number of clusters was 
determined using the gap statistic, as described below.   
 
5.3.8  Definition of the number of clusters in distance-based clustering 
 
With the use of distance-based clustering in class-discovery problems, the optimal 
number of clusters Kˆ must be estimated from the data.  We used the gap statistic [146] to 
test the null hypothesis that Kˆ  = 1 i.e. no clusters.  The optimal number of clusters was 
determined by comparing the within-cluster sum of squares to its expected value under a 
reference null distribution.  The reference distribution was generated from a uniform 
distribution aligned with the principal components of the data as described by Tibshirani 
et al.  Expression data was clustered into k groups (k = 1,2,...25) using either Kmeans or 
hierarchical clustering as described above.  A set of B reference datasets were generated 
by drawing samples from the reference distribution and clustered in the same manner.  
The gap statistic was calculated as: 
( ) ( ) ( )∑ −=
b
kkbk WWBGap loglog1
*                                   
 
in which Wkb*, (b=1,2,...B and k = 1,2,...25) and Wk are within-cluster sums of squares of 
the reference and observed datasets respectively.  The estimated number of clusters Kˆ  is 
the smallest value k at which: 
                                                       11 ++ −≥ kkk sGapGap                                              
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and sdk is the standard deviation of log(Wkb*). 
 
5.3.9  Model-based subspace clustering 
 
A model-based clustering algorithm [147], developed for the analysis of comparative 
genomic hybridization data, was used to cluster tissue samples on the basis of bimodal 
gene expression.  In this approach, clusters are identified by finding an optimal partition 
of samples into K groups defined by cluster-specific multivariate Gaussian distributions.  
It is assumed that clusters can be differentiated by shifts in the mean expression values 
for a subset of genes.  In the Hoff study, each sample is modeled as follows: 
 
                                                      iiii ry εδµ +×+=                                                 
 
in which μ is a vector of mean expression values over all samples, ri ϵ (0,1)m and 
indicates the relevant genes, δi is a vector of mean shifts and εi is a vector of the variance 
in expression values.  Cluster-specific parameters ϴ = (ri,δi) are sampled from a baseline 
distribution f0 in a Polya urn scheme or chinese restaurant process as described by Hoff:  
 
 
          sample ϴ1 ~ f0 
 
                                  sample ϴn ~ α/(α+n-1)f0 + (n-1)/(α+n-1)fn-1                                  
 
where fn-1 is the empirical distribution of ϴ1, ... , ϴn and a is a constant.  This process 
potentially results in less than n unique draws from the baseline distribution and therefore 
naturally leads to clustering.  Parameters of the model are fit from the data using a Gibbs 
sampling algorithm.  We ran the model-based clustering algorithm [147] in the R 
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statistical environment on 25 parallel Markov chains with 250 iterations each.  We found 
that each chain quickly converged to equally likely, unique solutions, indicating a multi-
modal posterior distribution.  To obtain an approximation of the true posterior 
distribution, we took the average of the cluster partition with the highest log-likelihood 
from each chain as reported elsewhere [67, 139]. 
 
5.3.10  Pairwise posterior probabilities  
Given a set of clusters obtained from Gibbs sampling, the probability that two 
observations belong to the same class is approximated by the proportion of clusters in 
which they are grouped together [139].  For each pair of samples, the pairwise posterior 
probability matrix was calculated as: 
                                     
clustersoftotal
ccwhichinclustersof
P jiij #
# =
=                                        
in which ci (i = 1,…, n samples) is a vector indicating which cluster sample i is assigned 
to.  Although the pairwise posterior probability is a useful measure in itself, it does not 
provide a single cluster partition.  For this purpose, a distance metric was defined from 
the pairwise posterior probabilities equal to Dij = 1 - Pij [139].  A unique cluster partition 
can then be found using the complete linkage method, such that objects are grouped 
together when the pairwise distance between them is less than one.  
 
5.3.11  Quantifying the agreement between observed clusters and known phenotype 
 
In this study, clustering algorithms were applied to data in which the true class 
membership of all samples was known a priori.  The Adjusted Rand Index (ARI) was 
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used to measure the amount of agreement between the known and estimated class 
membership [62, 67].  Given two partitions of n observations U = (u1,...,uR) and V = 
(v1,...,vC), where U indicates the cluster partition and V indicates the true class, the 
Adjusted Rand Index can be calculated from the contingency table of the two partitions 
(Table 3).  An element nij of the contingency table equals the number of observations in 
cluster i that are of class j.  Row sums of the contingency table are equal to ni. and 
column sums are equal to n.j. 
 
Table 3: Contingency table comparing two partitions 
  v1 v2 … vC   
U1 N11 N12 … N1C n1. 
U2 N21 N22 … N2C n2. 
… … …   … … 
uR nR1 nR2 … nRC nR. 
 n.1 n.2 … n.C n.. = n 
 
 
 
With this notation, the Adjusted Rand Index is calculated by the formula below and takes 
a value of 1 when the two partitions agree completely and a value of 0 when the index 
equals its expected value (i.e. the partitions are no better than random).                               
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5.3.12  Supervised Classification  
A multi-class supervised learning scheme was used to classify tissue samples on the basis 
of bimodal gene expression.   To extend the supervised learning scheme to multiple class 
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problems, we trained separate classifiers to identify tissue samples of each class vs. all 
others [148].  Results are based on 100 independent iterations of the following training 
and testing procedure.  Prior to classification, datasets were divided into training and 
testing sets in a class-proportional manner such that two-thirds of the samples in each 
class were used for training and one-third for testing.  For the jth classifier (j = 1,... , 
number of classes), training samples in class j were assigned to class 1.  All other samples 
were assigned to class 0.  Discriminative bimodal genes were identified from the training 
data according to the ratio of within class to between class sum of squares [85].  Diagonal 
linear discriminant analysis was used to define the distances between test sample i and 
samples in class 0 (dco) and class 1 (dc1), respectively [85].  A confidence measure, 
defined from 0 to 1, was calculated as dco/(dco+dc1).  Values close to 0/1 indicate low/high 
confidence that test sample i belongs to class j.  Confidence measures are compared from 
each classifier and test sample i is assigned to the class associated with the highest 
confidence.     
 
5.3.13  Simulated Data  
 
Synthetic data was used to determine the effect of sample size, effect size and the number 
of informative genes on prediction accuracy in binary classification.  In silico expression 
datasets consisted of 10, 20, 30, 50, or 100 observations/arrays and 1000 features/genes.  
Initially, a binary vector indicating the class membership of each observation was drawn 
from a binomial distribution B(n,0.5).  A number of 5, 10, 20, 50, or 100 informative 
gene expression profiles were drawn from a pair of multivariate normal distributions 
N1(μ1, Σ) and N2(μ2, Σ) representing each class of observations.  Non-informative 
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expression values representing noise genes were drawn from a mixture of N1 and N2 with 
mixing probabilities of ½ from each distribution.  A diagonal covariance matrix (Σ) was 
used to simulate independent expression values.  Effect size was measured by a 
separation parameter defined for each gene, specifically the distance in class-specific 
means divided by the pooled variance.  Three effect sizes (6, 2, 1) were investigated.  We 
used logistic regression to generate the response variable that indicates class membership 
from the expression data.  Regression coefficients associated with the informative genes 
were drawn from a uniform distribution U(0.1,1).  By logistic regression, the probability 
that the ith observation is class 1 is given by πi: 
 
                                           ( )iMMii xx ,,11exp1
1
ββ
π
+++
=

                                    (7) 
 
in which β1 … βM  are the defined regression coefficients and x1,i … xM,i are the expression 
values of the informative genes in the ith observation.  The simulated dataset was 
completed by drawing the response variable yi on the basis of πi (yi = 1 iff πi > 0.5).  In 
specified exactly (i.e. the value of β), independent of the sample distribution of gene j.   
 
5.4  Results 
5.4.1  Model-based clustering accurately classifies tissue phenotypes on the basis of 
bimodal gene expression 
 
A model-based classification algorithm [147] partitioned a set of 407 microarray data 
samples into bins specific to 19 different tissue types (Figure 13). Classification was 
based on expression of 1265 switch-like genes with bimodal gene expression patterns 
identified in human microarray data [134].  In model-based clustering, the number of 
clusters is optimized as part of the model-fitting process.  Each instance of model-based 
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clustering leads to slightly different results, with some tissue samples appearing in 
different clusters from run to run.  The posterior distribution of model-based cluster 
solutions captures the uncertainty in clustering and is approximated by summarization of 
the most likely partitions visited by the algorithm [66, 139].  To avoid the label-switching 
problem in summarization, in which the number and label of clusters differs between 
runs, we calculated the posterior pairwise probability that each pair of samples clusters 
together [62].  Heat maps shown in Figure 13 depict the posterior pairwise probability 
matrix for each pair of samples.  The color of element xij of the heat map indicates the 
number of partitions in which sample i and sample j are assigned to the same cluster, with 
yellow being the maximum and blue the minimum. Rows and columns of the heat map 
are organized to group samples of the same tissue type together.  The overlaid grid shows 
the boundary between different phenotypes. The figure shows that model-based 
classification correctly grouped microarray samples into tissue-specific clusters, even for 
tissues with as few as five microarray samples. 
 
Two distance-based clustering algorithms, Kmeans and hierarchical clustering, were also 
used to classify tissue phenotype for comparison.  We determined the optimal number of 
groups prior to distance-based clustering using the gap statistic [146].   Both distance- 
based clustering algorithms identified brain-specific and muscle-specific clusters but 
failed to differentiate between tissues with smaller number of samples (Figure 13). 
Partitions generated by model-based clustering reflect tissue phenotype more closely, as 
indicated by the yellow regions along the diagonal of the heat map (Figure 13).  
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Figure 13 - Model-based clustering of bimodal gene expression identifies cohesive 
clusters in 19 tissue types.  Heat map representation of posterior pairwise probabilities 
for classification of tissue phenotype.  Left column: classification with 1265 bimodal 
genes. Right column: classification with 300 bimodal genes translated into extracellular 
matrix or plasma membrane proteins.  Top row: Model-based clustering identifies all 
tissues distinctly. Middle and bottom rows: Kmeans and hierarchical clustering classify 
samples into three/four tissue types: brain, cardiac and skeletal muscle and remaining 
tissues.  Blue, green, yellow, orange and red regions of color bar indicate ovary, stomach, 
small intestine, pancreas and thymus tissue samples respectively. Tissues in the heat map 
were ordered according to decreasing sample size from left to right.  
 
 
 
To further quantify our results, we used the Adjusted Rand Index (ARI) to evaluate how 
well the clustering algorithms extracted the class structure present in the tissue phenotype 
dataset. The Adjusted Rand Index measures the amount of agreement between the true 
class membership and the observed cluster partitions [62, 67].  ARI is equal to one at 
perfect agreement whereas it is equal to zero when the agreement is no better than 
expected by chance.  Distance-based algorithms generate single partitions of the data that  
Table 4 – Adjusted Rand Index compares observed partitions with true 
classification of samples in tissue phenotype data 
 Kmeans Hierarchical Model-based 
All bimodal genes 0.291 0.463 0.683 
ECM/MEM genes 0.456 0.304 0.881 
 
 
 
are suitable for analysis with the ARI.  Prior to analysis of the model-based clusters, the 
posterior pairwise probability matrix was converted to a distance metric and a single 
partition was obtained via the complete linkage method [62].  As shown in Table 4, 
model-based clustering has significantly higher ARI values compared to distance-based 
clustering, especially for classification using a subset of bimodal genes in extracellular 
matrix and cell membrane GO categories.  Consistent with the heat maps shown in Figure 
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1, Table 2 shows that model-based clustering outperformed distance-based algorithms in 
unsupervised classification of tissue phenotypes.    
 
5.4.2  Bimodal genes specific to extracellular matrix and membrane cell compartments 
improve model-based clustering of tissue phenotypes  
 
Microarray samples profiling different tissue types were classified with a subset of 
bimodal genes whose products are expressed in the extracellular matrix (ECM) or on the 
plasma membrane (MEM). ECM and MEM genes are statistically enriched in the 
bimodal gene sets for the human [134]and the mouse[144].  Cell-cell or cell-ECM 
interactions, mediated through cell surface receptors, activate downstream transcriptional 
programs that regulate a diverse set of processes including growth, proliferation, 
apoptosis, and cell motility [149, 150].  A subset of ECM and membrane bound proteins 
are known to be tissue-specific and play crucial roles in the development and 
maintenance of tissue differentiation [151, 152].  Moreover, altered expression of ECM 
and MEM proteins has been linked to pathogenesis in muscular dystrophy, multiple 
sclerosis, and various cancers [153-155].   Using information obtained from the Gene 
Ontology database [44], 300 bimodal genes annotated with ECM or MEM terms were 
identified.  Model-based clustering based on expression of ECM and MEM bimodal 
genes led to more accurate classification.  Entirely separate clusters of skeletal and 
cardiac muscle were resolved.  Other tissue phenotypes were also identified with higher 
accuracy as indicated by the color of off-diagonal elements in the heat map and the ARI 
(Figure 13, Table 4).   Noting that the tissue-specific sample size in the microarray data 
ranged from 5 to 89 (Table 2), results with model-based classification indicate the 
strength of tissue-specific signatures in global gene expression and the ability of bimodal 
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genes to capture such signatures. Results also indicate that a subset of bimodal genes 
whose products are positioned either on extracellular matrix or the cell membrane is 
sufficient to identify tissue-specificity in microarray data.  Given the importance of ECM 
and MEM proteins in the regulation of cellular function, products of these genes may 
serve as candidate biomarkers or therapeutic targets in tissue-specific diseases.     
 
5.4.3  Bimodal genes classify more accurately than randomly selected genes  
 
Next, we clustered the tissue phenotype microarray datasets with randomly selected gene 
expression values.  In previous work, we had demonstrated the power of randomly 
selected genes in supervised classification of molecular phenotypes in gene expression 
data of various cancers [156]. Random datasets consisted of expression values from 300 
probe sets sampled without replacement from the total 22,277 probe sets analyzed.  A 
total of ten random datasets were clustered and the posterior pairwise probability was 
calculated as described above.  Both distance-based algorithms revealed a strong brain 
tissue expression signature, indicated by the observation that brain samples cluster 
together more often than with samples of other tissue types in random datasets (Figure 
14).  Kmeans clustering of random datasets also identified a strong muscle tissue 
signature (Figure 14).  For comparison, we clustered the tissue phenotype data using a 
similar number of bimodal genes (293), identified by increasing the stringency of the 
signature (Figure 14).  For comparison, we clustered the tissue phenotype data using a 
similar number of bimodal genes (293), identified by increasing the stringency of the 
tests used to detect bimodality.  Classification of brain and muscle tissue was more 
accurate with the use of these bimodal genes than the randomly selected gene sets (Figure 
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Figure 14 - Bimodal gene expression classifies tissue types more accurately than 
expression of randomly selected genes.  Heat map representation of posterior pairwise 
probabilities for classification by bimodal and randomly selected genes.  Top row: 
Kmeans clustering.  Bottom row: hierarchical clustering. Left column: classification with 
300 randomly selected genes on the microarray chip. Right column: classification with 
293 bimodal genes (p-value<=0.001 and area of intersection <= 0.01).  Blue, green, 
yellow, orange and red regions of the color bar indicate ovary, stomach, small intestine, 
pancreas and thymus tissue samples respectively.
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14).  Although there are strong brain and muscle tissue expression signatures in the data, 
bimodal genes appear to be enriched with more tissue-specific genes than expected by 
chance. 
 
5.4.4  Enrichment analysis reveals tissue-specific functions of "on" genes in brain, 
skeletal muscle, cardiac muscle, and lung tissue 
 
Functional enrichment identified gene sets related to tissue-specific function in sets of 
bimodal genes biased toward the "on" mode in a majority of samples of brain, skeletal 
muscle, cardiac muscle and lung tissue.   Bimodal gene expression values were binarized 
into "on" and "off" modes prior to analysis as described in Ertel & Tozeren [144].  A 
gene by sample heat map (Figure 15) shows the mode of expression for all 1265 bimodal 
genes in 217 samples of brain, skeletal muscle, cardiac muscle and lung tissue.   
 
 
Figure 15 – Binarized expression of bimodal genes in brain, lung, skeletal muscle 
and cardiac muscle.  Top figure: heat map of 1265 bimodal gene expression in 217 
tissue samples.  A black/white point at i,j indicates gene i is "on"/ "off" in sample j.  
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A black/white element xij of the heat map indicates gene i is expressed in the "on"/"off" 
mode in sample j.  Distinct clusters of "on" and "off" genes are observed in each tissue  
type.  In total, we identified 542, 429, 322, and 278 genes over-represented in the "on" 
mode and 645, 778, 830 and 896 genes over-represented in the "off" mode in brain, 
skeletal muscle, cardiac muscle and lung tissue respectively.  Functional enrichment 
analysis with gene sets defined by GO terms and KEGG pathways (Tables 5 and 6) 
provided a biological context to these sets of bimodal genes. Notably, neural tissue-  
specific processes including neural migration, adhesion, recognition and differention, 
nervous system development, and synaptic transmission populate the list of GO terms   
associated with genes that are "on" in brain tissue.  Similarly, terms related to muscle  
 
 
Table 5 – GO categories significantly enriched with “on” genes in brain tissue 
P-values <= 0.001 indicates significance. 
 
Biological Process Cellular Component Molecular Function 
 Neuron migration 
 Transport 
 Ion transport 
 Negative regulation of 
microtubule 
depolymerization 
 Cell adhesion 
 Neuron adhesion  
 Transmembrane receptor 
protein tyrosine 
phosphatase signaling 
pathway 
 Synaptic transmission 
 Neuromuscular synaptic 
transmission 
 Nervous system 
development  
 Synaptogenesis 
 Central nervous system 
development  
 Neuron recognition 
 Anterograde axon cargo 
transport 
 Neuron differentiation 
  Cytoskeleton  
  Microtubule 
  Microtubule associated   
complex 
  Neurofilament 
  Membrane 
  Integral to membrane 
  Synaptosome 
  Cell junction  
  Axon 
  Growth cone 
  Synapse 
  Postsynaptic membrane  
 Actin binding 
 GTPase activity  
 Transmembrane receptor 
protein tyrosine 
 Structural molecule activity 
 Strucutural constituent of 
cytoskeleton  
 Ion channel activity  
 Structural constituent of 
myelin sheath  
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Biological Process Cellular Component Molecular Function 
 Regulation of the force of 
heart contractionSM,CM 
 GlycolysisSM,CM  
 Tricarboxylic acid 
cycleSM,CM  
 Phosphate cycleSM,CM  
 Muscle contractionSM,CM  
 Striated muscle 
contractionSM,CM  
 Cytoskeleton organization 
and biogenesisSM,CM  
 Muscle developmentSM,CM  
 Regulation of heart 
contractionSM,CM 
 Muscle thin filament 
assemblySM,CM  
 Actomyosin structure 
organization and 
biogenesisSM,CM  
 Negative regulation of 
heart contractionSM,CM  
 Atrial cardiac muscle 
morphogenesisSM,CM 
 Carbohydrate metabolic 
processSM 
 Glycogen metabolic 
processSM 
 Glycogen biosynthetic 
processSM 
 GluconeogenesisSM 
 Protein amino acid 
dephosphorylationSM 
 Regulation of muscle 
contractionSM 
 Regulation of striated 
muscle contractionSM 
 Somatic muscle 
developmentSM 
 Blood circulationSM 
 DephosphorylationSM 
 Maintainance of epithelial 
cell polaritySM 
 Glycerol-3-phosphate 
catabolic processSM 
 Response to unfolded 
proteinCM 
 Cell adhesionCM 
 Cell-matrix adhesionCM 
 Heart developmentCM 
 Adult heart developmentCM 
 ATP transportCM 
 Focal adhesion 
formationCM 
 CytoplasmSM,CM 
 Smooth endoplasmic 
reticulumSM,CM 
 CytoskeletonSM,CM 
 Striated muscle thick 
filamentSM,CM  
 Actin cytoskeletonSM,CM 
 Sarcoglycan complexSM,CM 
 Sarcoplasmic 
reticulumSM,CM 
 MyofibrilSM,CM 
 SarcomereSM,CM 
 Z discSM,CM 
 MitochondrionSM 
 Mitochondrial inner 
membraneSM 
 Mitochondrial matrixSM 
 Muscle myosin complexSM 
 Troponin complexSM 
 Actin filamentSM 
 Myosin complexSM 
 Sarcoplasmic reticulum 
membraneSM 
 Sarcoplasmic reticulum 
lumenSM 
 Proteinaceous 
extracellular matrixCM 
 
 
 Actin bindingSM,CM  
 Citrate (Si)-synthase 
activitySM,CM  
 Electron-transferring-
flavoprotein 
dehydrogenase 
activitySM,CM 
 Extracellular matrix 
structural constituentSM,CM 
 Calcium ion bindingSM,CM 
 Structural constituent of 
muscleSM,CM  
 SSM00 alpha bindingSM,CM 
 Microfilament motor 
activitySM 
 Motor activitySM 
 Catalytic activitySM 
 NADH dehydrogenase 
activitySM 
 Glycerol-3-phosphate 
dehydrogenase (NAD+) 
activitySM 
 Calmodulin bindingSM 
 Tropomyosin bindingSM 
 Electron carrier activitySM 
 Oxidoreductase activity, 
acting on CH-OH group of 
donorsSM 
 Oxidoreductase activity, 
acting on the CH-OH 
group of donors, NAD or 
NADP as acceptorSM 
 Hydrolase activity, acting 
on acid anhydrides, 
catalyzing transmembrane 
movement of 
substancesSM 
 Spectrin bindingSM 
 NAD bindingSM 
 Structural molecule 
activityCM 
 Structural constituent of 
cytoskeletonCM  
 Protein bindingCM 
 Adenine transmembrane 
transporter activityCM 
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Table 6 – GO categories significantly enriched with “on” genes in skeletal and/or 
cardiac muscle  
P-values <= 0.001 indicate significance. SMskeletal muscle, CMcardiac muscle 
 
 
 
development and organization, muscle contraction, calcium ion binding, cellular 
metabolism and muscle-specific structures such as the sarcoplasmic reticulum, myofibril, 
sarcomere and z disc are found in the list of enriched GO terms associated with skeletal 
and cardiac muscle.  A number of KEGG pathways are also enriched (Table 7).  The 
KEGG diagram summarizing cell adhesion molecules is enriched with genes turned "on" 
in brain tissue and genes turned "off" in muscle tissue (Figure 16).  Several of these cell 
adhesion molecules, such as CDH2, NCAM, NRXN, and NLGN, are expressed at  
 
Table 5 – KEGG pathways enriched with “on” genes in brain, skeletal muscle, 
cardiac muscle and lung tissue  
P-values <= 0.001 indicate significance.  Bbrain, SMskeletal muscle, CMcardiac muscle, 
Llung 
 
KEGG Pathways 
 Cell adhesion molecules (CAMs)B 
 Long-term depressionB 
 Neurodegenerative diseasesB 
 Tight junctionB,SM 
 Calcium signaling pathwaySM 
 Carbon fixationSM 
 Citrate cycle (TCA cycle)SM 
 ECM-receptor interactionSM,CM,L 
 Focal adhesionSM,CM,L 
 Glycolysis / GluconeogenesisSM,CM 
 PPAR signaling pathwaySM,CM 
 Reductive carboxylate cycle (CO2 
fixation)SM,CM 
 Cell CommunicationCM,L 
 Pyruvate metabolismCM 
 Adherens junctionL 
 Complement and coagulation cascadesL 
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Figure 16: Bimodal gene expression in KEGG cell adhesion molecules diagram.  
Genes marked with red are "on" in brain tissue and "off" in muscle tissue.  Genes marked 
with yellow are "off" in muscle tissue.  
 
 
synaptic junctions [157].  Another subset, including NFASC and CNTNAP2, is integral 
to the formation of myelinated neurons [158].  Statistical enrichment of GO terms and 
KEGG pathways associated with tissue-specific structure and function provides further 
evidence that our bimodal gene set exhibits tissue-specific expression patterns. 
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5.4.5  Model-based classification of infectious disease and immune response signature 
 
Model-based clustering of bimodal gene expression led to accurate classification of 
disease phenotypes in 221 microarray tissue samples profiling infectious 
disease.Peripheral blood mononuclear cells (PBMC) present in the circulation and 
lymphatic system recognize pathogen-specific molecules and initiate the immune 
response [159].  Pathogen recognition induces transcriptional activation of several host 
defense signaling pathways [160].  The posterior pairwise probability matrix derived 
from model-based clustering partitioned expression profiles of PBMCs into disease-
specific clusters for HIV-1 infection, hepatitis C, influenza, and malaria (Figure 17). 
Moreover, model-based clustering differentiated between samples of hepatitis C infection 
in PBMCs and liver biopsies (Figure 17). These results suggest that model-based 
clustering captures infectious disease signatures in microarray data in a tissue-specific 
manner.  In addition, a different set of bimodal genes may be selectively expressed in 
PBMCs in infectious disease states induced by different pathogens.      
 
Enriched functional gene sets related to the immune response were detected in sets of 
active switch genes in infectious disease samples.  Of the 1295 bimodal genes analyzed, 
192, 160, 148 and 117 genes were expressed in the “on” mode in the majority of samples 
from PBMCs in hepatitis C, influenza A, malaria, and HIV   respectively.  In liver 
biopsies from hepatitis C infected individuals, 301 bimodal genes are over-represented in 
the “on” mode.  Table 6 lists the GO terms that are statistically enriched in Hepatitis C, 
influenza, and malaria infection. Biological processes commonly enriched in the set of 
bimodal genes expressed in the “on” mode in these diseases include B cell receptor 
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Figure 17 – Model-based clustering of bimodal gene expression classifies infectious 
disease states separately and identifies tissue-specificity in hepatitis C infection.  
Heat map representation of pairwise posterior probabilities derived from model-based 
clustering of infectious disease expression data.  Left column: Classification of hepatitis 
C, HIV, influenza A, and malaria profiled in peripheral blood mononuclear cells 
(PBMCs).  Right column: Classification of hepatitis C infection profiled in peripheral 
blood mononuclear cells and liver biopsies. 
 
 
 
 signaling [161, 162] and humoral immune response involving circulating 
immunoglobulins [163].  These processes are central in the activation of the antigen-
mediated, adaptive immune system.  Bimodal genes upregulated in hepatitis C infection 
in PBMCs are associated with inflammatory response, respiratory burst and altered 
response to calcium ions (Table 8) [164].  Both inflammation and the production and 
release of oxidative species are important components of the innate immune response 
[165].  Enrichment of gene sets associated with function of the immune system and 
leukocyte-specific receptor signaling pathways suggests that a subset of genes with 
bimodal expression patterns are relevant in the host-response to pathogens. 
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Table 8 – GO categories significantly enriched with “on” genes in infectious disease   
P-values <= 0.001 indicate significance in malaria, influenza A, hepatitis C-PBMCs and 
hepatitis C-Liver.  P-values <= 0.01 indicate significance in HIV.  1malaria, 2influenza A, 
3HIV, 4hepatitis C-PBMC, 5hepatitis C-liver   
 
Biological Process Cellular Component Molecular Function 
 Immune response1,2,3,4,5  
 Humoral immune response 
by circulating 
immunoglobin1,2,4,5  
 Positive regulation of B cell 
proliferation1,2,4,5 
 Early endosome to late 
endosome transport1,2,4,5 
 Positive regulation of 
peptidyl-tyrosine 
phosphorylation1,2,4,5 
 B cell receptor signaling 
pathway1,2,4,5 
 Activation of MAPK 
activity1,2,4 
 tRNA aminoacylation for 
protein translation1,4  
 Antigen processing and 
presentation1,4  
 DNA methylation3 
 Translational initiation3 
 Negative regulation of 
protein kinase activity3 
 Defense response3 
 Inflammatory response4 
 Hemocyte development4  
 Cell-cell adhesion4  
 Pyridine nucleotide 
biosynthetic process4  
 Respiratory burst4  
 Response to calcium ion3,4  
 Tricarboxylic acid cycle5 
 Cell adhesion5 
 Blood coagulation5 
 Sensory perception of 
sound3,5 
 
  B cell receptor 
complex1,2,4,5  
  Immunoglobulin complex, 
circulating1,2,4,5  
  Perinuclear region of 
cytoplasm1,2,4,5  
  External side of plasma 
membrane1,4  
  Membrane fraction4,5  
  Cytoplasm3,5  
  Cytoskeleton3  
  Actin cytoskeleton3  
  Extracellular region5   
  Proteinaceous extracellular 
matrix5   
  Collagen5  
 
 Antigen binding1,2,4,5  
 Succinate dehydrogenase 
activity2,3,4  
 RNA binding3 
 Structural constituent of 
cytoskeleton3 
 Protein binding3 
 Electron-transferring-
flavoprotein 
dehydrogenase activity5 
 Endopeptidase inhibitor 
activity5 
 Structural molecule 
activity5 
 Extracellular matrix 
structural constituent5  
 
 
 
 
 
Gene Ontology enrichment analysis for switch-like genes turned “on” in HIV1 infection 
indicated the biological processes of DNA methylation, translational initiation, negative  
regulation of protein kinase activity, and response to calcium (Table 8).  Statistically 
enriched KEGG pathways for HIV-1 infection included focal adhesion and adherens 
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junction, leukocyte migration, natural killer cell mediated cytotoxity, B-cell and T-cell 
receptor signaling pathways. Bimodal genes that are observed to be expressed in the “on” 
mode in the T-cell signaling pathway include membrane protein CD45 [166], kinase 
activator SLP-76 [167], RAS proteins RASGRP1 and Rho Cdc42, calcium are  involved 
in binding protein CaN, and the transcription factor AP1 [168] (Figure 18). These 
proteins multiple pathways and processes including ubiquitin mediated proteolysis, 
regulation of actin cytoskeleton, and proliferation and differentiation of the immune 
response.  Many of these processes/genes are involved in the hijacking of normal T-cell 
function by HIV for the production, modification and release of viral proteins.  
 
5.4.6  Supervised classification with bimodal genes capture tissue-specificand 
infectious disease specific signatures in microarray data 
 
We implemented a multi-class supervised classification scheme to estimate whether 
tissue/infectious disease-specific bimodal gene expression signatures were conserved in 
independent data.  Each dataset was split into training and test sets in a class-proportional 
manner.  Training data was used to select the 5 most discriminative switch-like genes and 
generate multiple binary decision rules.  Each decision rule was trained to recognize one 
class versus all others [148].  Test samples were classified with the decision rules trained 
on independent data to provide an unbiased evaluation of the association of bimodal gene 
expression with class distinction.  As a control, we also trained classifiers on the basis of 
genes selected randomly from the entire gene chip.  Results over 100 independent 
iterations of training and testing are shown in Tables 9 and 10.  Prediction of tissue-  
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Figure 18 – Bimodal genes that were switched “on” as a result of HIV infection in KEGG T-cell receptor signalling pathways.  
Bimodal genes marked with red are “on” in the KEGG T-cell receptor signaling pathway in HIV infection. 
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specificity was accurate in 85 % of test samples for all tissues except colon (10 samples), 
mammary (15 samples), small intestine (7 samples) and testis (38 samples).    
Misclassified tissue samples were often classified as similar tissue types.  For example, 
microarray samples from small intestine tissue were predicted to be either muscle tissue 
or pancreatic tissue in 30% and 24% of test samples respectively.  These results indicate 
the persistence of cell-type-specific expression signatures in heterogeneous tissue 
samples.  Notably, 14% of testis samples were misclassified as ovary, indicating a subset 
of bimodal genes may be similarly expressed in reproductive organs of the male and 
female.  Supervised classification of infectious diseases based on switch-like genes 
showed similar accuracy (Table 10).  Multi-class supervised classification separated 
microarray samples from HIV-1 infection, hepatitis C and malaria well but it has 
allocated 22% of the influenza microarray samples to the bin for hepatitis C. This is not 
surprising in the light of our findings showing common immune signaling responses for 
these two viral infections (Table 8).  In both the classification of tissue phenotypes and 
infectious disease, feature selection was more accurate than random selection. These 
results indicate that tissue-specific and disease-specific bimodal gene expression profile 
signatures are conserved in independent data. 
 
5.4.7 Effect of sample size, effect size and number of informative genes on 
classification accuracy 
 
Supervised classification of simulated gene expression profiles illustrated the strong 
dependence of prediction accuracy on sample size, effect size and the number of 
informative genes (Figure 19).  In this minimal model, simulated datasets were designed 
to approximate binary classification.  A response variable indicative of class membership 
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Table 9 – Classification accuracy in supervised clustering of tissue phenotypes 
Values equal the proportion of true class versus predicted class membership over 100 
iterations of training and testing.  Values representing correct classification are outlined 
in bold.  
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adipose 0.89 0.11
adrenal 1
brain 0.01 0.99
colon 0.77 0.12 0.02 0.06 0.01
epidermal 0.01 0.97 0.02
heart 1
kidney 0.08 0.86 0.01 0.01 0.04
liver 1
lung 0.97 0.01 0.01 0.01
mammary 0.08 0.13 0.79
muscle 1
ovary 0.02 0.97 0.01
pancreas 0.91 0.06 0.02
peripheral_blood 0.88 0.09 0.03
small_intestine 0.3 0.24 0.44 0.01 0.01
spleen 0.01 0.04 0.02 0.92
stomach 0.01 0.03 0.02 0.95
testis 0.05 0.01 0.14 0.01 0.03 0.73 0.03
thymus 0.12 0.01 0.86
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Table 10 – Classification accuracy in supervised clustering of infectious disease  
Values equal the proportion of true class versus predicted class membership over 100 
iterations of training and testing.   
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was generated from expression profiles of informative genes via logistic regression.  
Informative gene expression profiles were drawn from a pair of multivariate normal 
distributions.  Expression profiles representing noise genes were generated from a 
mixture of these distributions.  Separation between the two distributions was defined in 
terms of the difference in class-specific means and the pooled variance.  Bimodal gene 
expression was assumed to hold when setting the separation equal to the median  
separation between “on” and “off” modes of switch-like expression profiles (μ1-μ2 = 6σ2).   
Smaller separation values (μ1-μ2 = 2σ2, μ1-μ2 = σ2) simulate expression profiles that are 
less bimodal and more normally distributed (Figure 19).  Supervised classification was 
applied as described above and classification accuracy was assessed using the area under 
the receiver-operating characteristic curve (AUC) (Figure 19).  Results are based on the 
average AUC generated from 100 simulated datasets for each condition.  Classification 
accuracy generally improved as expression profiles became more bimodal (Figure 19).  
Increased sample size and decreased number of informative genes also resulted in more 
accurate classification as well (Figure 19).   
 
5.5  Discussion  
Development and subsequent commercialization of microarray platforms has led to 
extensive investigation of global gene expression profiles in health and disease. 
Expression profiling of diverse healthy tissues provides a comprehensive perspective of 
the range of transcriptional regulation under physiologic conditions [169-171].  Similarly, 
identification of gene expression signatures indicative of disease subtypes improves our 
understanding of the molecular basis of pathology [135, 136].  Small sample size and the
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Parameters 
- Effect size (μ1-μ2/σ2) 
- Regression coefficients (β) 
- Number of samples (n)  
- Number of genes (p) 
- Number of significant genes (M)  
- Number of selected features (N) 
 
 
Figure 19 – Effect of sample size, separation and number of informative genes on 
classification of simulated expression data. Classification accuracy is measured with 
the area under the receiver operating characteristic curve.  
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large number of measurements for each sample are among the limiting factors that hinder 
the effectiveness of gene expression profiling and drive the development of new 
analytical methods. 
 
Unsupervised clustering of microarray data classifies samples in an unbiased manner 
according to similarity in gene expression profiles.  Adaptation of model-based clustering 
to low sample size, high dimensional datasets [66] and formalization of statistical 
approaches for selecting the optimum number of clusters [146] represent significant 
advances.  In this study, we used these advanced methods to cluster and classify 
infectious disease and tissue phenotypes in large scale microarray data using a reduced 
set of 1265 genes, the so-called switch-like genes [134].  Switch-like genes are identified 
through the detection of bimodal gene expression patterns across diverse biological 
conditions.  Switch-like genes are likely to be under strict transcriptional regulation and 
are statistically enriched for cell membrane and extracellular proteins [144]. 
 
We demonstrated that model-based clustering of switch-like gene expression patterns 
differentiates between tissue phenotypes in a microarray dataset with tissue-specific 
sample sizes ranging from 5 to nearly 100.  Model-based clustering operates on the 
assumption that samples are drawn from multivariate Gaussian distributions.  Clusters are 
defined by identifying shifts in the mean expression value for a subset of genes.  Based 
on this description, model-based clustering is particularly well-suited for the analysis of 
bimodal gene expression profiles.  Annotation of genes with cellular localization 
information allowed us to identify a subset of 300 bimodal genes expressed on the 
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extracellular matrix or the plasma membrane.  This set includes membrane-bound 
integrin proteins and ECM proteins belonging to collagen, laminin, and fibronectin 
families.  Accurate classification of tissue type with this subset of bimodal genes supports 
the hypothesis that interaction with the cellular micro-environment has a significant role 
in tissue differentiation [151, 152].  Distance-based unsupervised classification methods 
such as Kmeans and hierarchical clustering also identified brain-specific and muscle-
specific clusters with sample sizes above 40 but they tended to group tissues with few 
microarray samples together.  Classification accuracy will likely improve with increasing 
sample size.   
 
Model-based clustering of the set of 1295 bimodal genes correctly placed microarray 
samples into bins identified for HIV-1 infection, hepatitis C, influenza and malaria.  In 
this classification, each disease type might have multiple bins depending on tissue type 
and/or laboratory from which microarray data came from. The method classifies hepatitis 
C microarray samples from liver biopsies into a separate bin rather than mixing it with 
microarray data on peripheral blood cells from hepatitis C patients. Similarly, microarray 
data on HIV-1 infection turned out to be classified into laboratory-specific bins. This 
differentiation may be due to distinctly different patient pools in different laboratories as 
well as the small sample size in disease microarray sets. Nonetheless, these results 
indicate the promise of model-based classification in the identification of infectious 
disease subtypes from microarray data.    
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Identification of on-off states of switch-like genes in microarray data allowed us to assess 
the biological relevance of the alternate switch states of these genes in various infectious 
diseases and tissue phenotypes. Comparison of activated switch-like gene sets between 
tissue and disease phenotypes provide a measure of distance between different 
phenotypes.  We observed that genes expressed in the “on” mode in brain tissue and the 
“off” mode in muscle tissue code for neural-specific cell adhesion molecules.  In 
addition, bimodal genes switched “on” in brain, skeletal muscle and cardiac tissue are 
related to tissue-specific structure and function.  In the infectious disease states 
investigated here, bimodal genes expressed in the “on” mode are related to both innate 
and antigen-mediated immune responses.  Additionally, in HIV samples, “on” genes are 
expressed in pathways related to the hijacking of infected T-cells for viral production.  
The large body of evidence presented in the results section points to the success of 
switch-like gene sets in capturing biologically-relevant global gene expression signatures 
from microarray data.  
 
Given the demonstrated biological relevance of bimodal expression patterns, it would be 
worthwhile to determine the clinical relevance of switch-like gene annotation.  
Identification of bimodal genes expressed in the on state in complex diseases such as 
autism, diabetes and cancer may provide a method for dimension reduction in the 
identification of disease-related single nucleotide polymorphisms (SNPs) [34, 172-175] 
and expression quantitative trait loci (eQTL) [176, 177] in genome-wide association 
studies. Both gene sequences and promoter regions of on switch genes as determined 
from large scale microarray data could be searched for SNPs and eQTL linked to the 
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onset of disease or disease progression. Further studies are needed to investigate the full 
potential of clinically relevant classification using switch-like gene annotation from 
microarray data. 
 
We also addressed the question of whether tissue-specific or infectious disease bimodal 
expression signatures are conserved in independent data.  Unsupervised clustering 
algorithms use all of the data to identify similar expression profiles: these algorithms may 
reveal patterns associated with random noise.  Supervised classification algorithms test 
for random associations by separating the data into independent training and testing sets.  
A multi-class supervised classification scheme was implemented.  In both tissue 
phenotype and infectious disease datasets, a majority of test samples were correctly 
classified using as few as five genes.  Classification on the basis of discriminative 
bimodal genes was more accurate than classification by control sets of genes selected 
randomly from the entire microarray chip.  Moreover, our simulation results presented in 
Figure 19 indicate that tissue and infectious disease specific bimodal expression 
signatures are likely to be conserved in independent data at large sample sizes. 
 
5.6  Conclusion 
In this study, we used advanced clustering and classification algorithms to investigate 
expression profiles of switch-like genes in multiple tissue and infectious disease 
phenotypes.  Switch-like genes are defined as those genes with bimodal expression 
patterns in large-scale microarray data containing hundreds of samples across different 
tissue types.  Use of a model-based clustering algorithm accurately classified more than 
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400 microarray samples into 19 different tissue types on the basis of bimodal gene 
expression.  The algorithm demonstrated similar accuracy in the classification of 
microarray data corresponding to hepatitis C, influenza, HIV-1 infection and malaria.  
Classification accuracy was exceptional even with class-specific sample sizes between 
ten and twenty arrays.  Supervised classification with feature selection restricted to 
switch-like genes also recognized tissue-specific and infectious disease specific 
signatures in independent test datasets reserved for validation. Moreover, our 
computational simulations with a minimal model of microarray data indicated the validity 
of our observations in a large number of circumstances.  A set of 300 genes out of the 
1295 genes annotated in the human as switch-like coded for either extracellular matrix or 
cell membrane proteins.  This subset was equally good in differentiating distinct tissue 
types, indicating a potential role for them as biomarkers provided that expression is 
altered in the onset of disease.  Determination of “on” and “off” states of switch-like 
genes in various tissues and diseases allowed for prediction of activated/deactivated 
genes/pathways that are consistent with existing research data.  Future work is needed to 
address the question of whether switch-like gene expression has clinical implications in 
disease subtype classification.
  
93 
Chapter 6: Identification of autism risk loci around neural-specific bimodal genes 
 
6.1 Summary  
 
This chapter discusses an association study of high-density genomic data obtained from a 
multiplex cohort of 189 families affected by autism compiled by the Autism Genetic 
Resource Exchange (AGRE).  Autism is a heterogeneous neurodevelopmental disorder 
that is characterized by impaired social interaction and communication and repetitive 
behavioral patterns.  Epidemiological evidence suggests a strong heritable component 
transmitted by multiple genetic loci.  Candidate gene regions likely to contain genetic 
variants associated with autism risk were identified using gene expression analysis of a 
microarray dataset profiling 19 different tissue types.  We defined a set of genes with 
bimodal expression patterns across all tissues and high levels of expression in a majority 
of brain samples as neural-specific switch-like genes.  The coding and cis-regulatory 
regions of these genes were used as candidate gene regions.  Cis-regulatory regions were 
conservatively identified using a 1 Megabase window centered at the midpoint of the 
gene coding region.  Autistic individuals in this study were identified by positive 
diagnosis from the Autistic Diagnostic Interview-Revised (ADIR) and the Autism 
Diagnostic Observation Schedule (ADOS).  A two-stage family-based association test 
(FBAT) strategy was used to test for association and correct for multiple testing.  With 
this procedure, we identified a single nucleotide polymorphism (refSNP identifier: 
rs17101921) associated with autism with genome-wide significance in the q26 region of 
chromosome 10.  Subjects with the A allele at this locus are more likely to be diagnosed 
with autism (odds ratio = 1.31, 95% confidence interval (0.81 – 2.11).  Although none of 
the other screened SNPs in the region demonstrated association with autism, linkage 
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disequilibrium analysis identified a 13 Kilobase haplotype block containing the 
rs17101921 SNP.  The rs17101921 single nucleotide polymorphism (SNP) is located 
approximately 80 Kilobases upstream of the fibroblast growth factor 2 gene (FGFR2).  
FGFR2 is highly expressed in glial cells of the central nervous system and is involved in 
nervous system development and repair after injury.  Our study presents a novel method 
for integrating information obtained from gene expression and genotype analysis.  
Results of our study suggest new experiments regarding the investigation of the 
molecular basis of autism.   
 
6.2 Background  
 
Autism is one of a spectrum of neurological disorders that present with a combination of 
impaired social interaction, difficulties with communication, and repetitive behavior 
patterns.  Autism has been linked to several environmental and genetic risk factors.  .  
Approximately 10-15% of autism cases can be linked to chromosomal abnormalities such 
as fragile X syndrome, tuberous sclerosis or rare single gene disorders [178].  
Epidemiological studies of disease concordance in familial and twin studies indicate a 
heritable genetic component of disease.  Prevalence in males is four times higher than in 
females [179], suggesting that autism risk may be partially transmitted by loci on the X 
chromosome.  Sibling recurrence risk (5-10%) is significantly greater than prevalence in 
the general population (0.15-0.2%) [180].  In addition, identical twins show much higher 
concordance (60%-92%) than fraternal twins (0-10%) [181].  Taken together, these 
findings suggest that autism susceptibility is partially conferred by variation at multiple 
genetic loci.   
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Several independent genetic linkage and association studies have been conducted to 
identify genetic variants associated with autism susceptibility.  In linkage analysis, a set 
of genetic markers spaced widely throughout the genome are sequenced to detect regions 
of co-transmitted loci at low resolution.  Studies of extensive pedigrees of autism affected 
families have identified linkage regions in the short arms of chromosomes 2, 3, 6, 7, 10 
and 17 [182-185].  Association studies identify alleles at specific loci that are observed in 
affected individuals more than expected by chance.  Fine-mapping of candidate genes in 
chromosomal regions identified from linkage analysis has identified a number of putative 
autism susceptibility loci.  Genetic variants in the transcript region of the glutamate 
receptor 6 (GluR6) gene have been associated with increased autism risk [186].  The 
glutamate receptor functions in the excitation of neural signaling at post-synaptic 
junctions [187].  Similarly, variants in the laminin beta-1 (LAMB1) and engrailed 2 
(EN2) genes, have been associated with autism.  Products of both of these genes 
participate in the regulation of neurodevelopment [188, 189].  Additionally, autism-
associated polymorphisms have been detected in the upstream regulatory and intronic 
regions of the serotonin-transporter gene (SLC6A4).  SLC6A4 regulates the effect of 
serotonin by re-absorbing the neurotransmitter from the synaptic cleft [187].  Significant 
associations have been reported at several more genetic loci but these results have not 
been replicated in follow-up studies.   
 
Recent technological developments and the identification of common genetic variants, or 
single nucleotide polymorphisms (SNPs), make it possible to survey genetic variation at 
relatively high resolution.  Single nucleotide polymorphisms (SNPs) are individual 
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nucleotide bases in the genetic code that vary from person to person.  Extensive genetic 
mapping has identified a set of common SNPs expressed in at least 5% of the population 
[23, 24].  With this knowledge, gene mapping microarray platforms capable of evaluating 
association at a genome-wide scale have been developed.  SNP profiling technologies 
such as these can be used to provide a more detailed evaluation of the common genetic 
variants involved with autism risk. 
 
Genome-wide association studies are burdened with an exceedingly large multiple testing 
problem.  Procedures which control the type I error rate are applied to adjust p-values for 
the number of hypotheses tested and maintain genome-wide significance.  Conservative 
multiple testing corrections such as the Bonferonni correction are likely to eliminate a 
high number of true positive associations [56, 57].  The severity of multiple testing 
corrections can be reduced by decreasing the number of SNPs prior to association testing.  
A priori biological knowledge can be used to identify genes that are suspected to be 
involved with disease processes.  Association tests are then limited to the coding and 
regulatory regions of these candidate genes.  In family-based studies, statistical methods 
have been developed to screen for SNPs on the basis of conditional power estimates 
[190].  Only the most promising SNPs are tested for association.  By reducing the number 
of hypotheses tested, genome-wide significance can be assessed at less stringent 
thresholds.   
 
In this study, we have detected putative autism susceptibility loci in the coding and cis-
regulatory regions of candidate genes identified from gene expression analysis.  In 
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previous work, we identified 1265 genes with bimodal or switch-like expression patterns 
in diverse human tissues.  A subset of these bimodal genes are over-expressed in brain 
tissue and are known to be involved with neural development and function.  Using 
genotype and phenotype data of individuals in 189 autism-affected families compiled by 
the Autism Genetic Resource Exchange (AGRE) [191], we scanned the coding and 
regulatory regions of these genes for genetic loci associated with autism susceptibility.  A 
two-stage family-based association test was applied to screen for promising SNPs on the 
basis of conditional power estimates and test for association.  Our scan of the candidate 
gene regions identified a SNP upstream of the fibroblast growth factor receptor 2 
(FGFR2) gene associated with autism risk.  FGFR2 is known to have important roles in 
neurodevelopment [192] but has not previously been associated with autism through 
genomic study.  The autism susceptibility locus identified in this study provides evidence 
supporting novel hypotheses regarding the molecular origins of autism. 
 
6.3 Methods and materials  
  
6.3.1  Gene expression, genotype and phenotype data  
 
Gene expression data of approximately 400 samples from 19 different tissue phenotypes 
was compiled (Table 2).  Expression profiles were generated using the HGU133A and 
HGU133Plus2 Affymetrix platforms.   Only probesets common to both arrays were 
retained, leaving 22277 probesets for downstream analysis.  
 
Genotypic and phenotypic data compiled from family-based studies of autism were 
obtained from the Autism Genetic Resource Exchange (AGRE) [191].  Approval was 
obtained from the institutional review board of Drexel University prior to requesting the 
  
98 
data.  Genotypes were generated using the Affymetrix Genome-Wide Human SNP Array 
5.0 platform which contains probesets representing approximately 400,000 SNPs.  The 
subject population consists of 721 simplex and multiplex pedigrees with approximately 
1385 affected individuals.  Subjects were screened for common chromosomal aberrations 
associated with autism, such as Fragile X syndrome.  Subjects with chromosomal 
abnormalities or other non-idiopathic conditions were excluded to reduce phenotypic 
heterogeneity.  Additionally, families were excluded on the basis of incomplete 
genotyping.  Only families in which both parents and one or more affected children were 
genotyped were included.  To account for population stratification, only self-identified 
Caucasian subjects were included.  Filtering by chromosomal abnormalities, incomplete 
pedigree, and race resulted in the exclusion of 250 families.  
 
Diagnosis of autism is based largely on the Autism Diagnostic Interview-Revised (ADI-
R) algorithm [193].  In addition, the Autism Diagnostic Observation Schedule (ADOS) 
can be used to distinguish between autism and other pervasive developmental disorders 
such as Asperger’s and PDD-NOS [194].  In our analysis, affected individuals were 
identified by autism diagnoses by both the ADI-R and ADOS.  Furthermore, only 
families with two or more affected individuals were included.  Use of the multiplex 
diagnostic specifications described above resulted in the inclusion of 189 affected 
families, with 808 subjects and 392 autistic subjects.   
 
6.3.2  Pre-processing and quality control  
 
Reference robust multi-chip averaging (refRMA) [50] was used for normalization of 
microarray data, as described in the analysis of switch-like expression patterns.  Briefly, 
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RMA background adjustment was applied to each array, arrays are normalized with 
quantile normalization on the basis of a reference empirical distribution derived from a 
biologically diverse training set of arrays, and normalized probe intensities are adjusted 
to account for probe affinity effects derived from the training data.  Following 
background correction and normalization, summarized probe set expression values are 
obtained from the median value of constituent probe level intensities.  
 
Raw data derived from gene mapping arrays was pre-processed by the AGRE using the 
Birdseed algorithm.  Birdseed is used for normalization and summarization of probe-level 
data and genotype calling [51, 195].  Briefly, quantile normalization is used to correct for 
chip-specific effects.  A log transformation is used to obtain corrected log-scale probe-
level intensity measures.  Median polish is used to adjust for probe-specific effects and 
derive summarized allele-specific signal values (A and B alleles).  A model-based 
clustering approach is used to estimate the genotype of each sample at each SNP location.  
Clusters of genetic loci are generated by plotting the fluorescent signal derived from A 
allele probes versus the signal from B allele probes. Gentoypes are called by fitting SNP-
specific Gaussian mixture models to the signal values in this two-dimensional space 
using expectation maximization.  Following normalization and genotype calling, a 
number of quality control measures were implemented with the PLINK program [196] to 
screen for potential genotyping errors.  Mendelian inconsistencies in family pedigrees 
were identified and eliminated by setting the corresponding alleles to missing.  Exact 
tests of Hardy-Weinberg equilibrium (HWE) were evaluated for each SNP based on the 
genotype of the founders in each pedigree.  Loci with > 10% missing values, HWE p-
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values < 0.001 or minor allele frequencies < 0.05% were discarded prior to linkage 
analysis.  Implementation of quality control measures resulted in the removal of 
approximately 15% of the genotyped SNPs.  
 
6.3.3 Identification of candidate autism susceptibility loci  
 
Candidate genes with a priori relevance in neural development and function were 
identified using a statistical method to detect bimodality [140, 141, 144] in gene 
expression patterns in diverse human tissue.  Bimodal genes were identified using a log-
likelihood ratio test to test the alternative hypothesis that expression distributions fit a 
two-component Gaussian mixture model (GMM) versus a null normal distribution.  P-
values were obtained from evaluating the chi-square distribution at the values of the test 
statistic with six degrees of freedom.  Genes with p-values < 0.001 and a standardized 
area of intersection between the distributions of the component Gaussians less than or 
equal to 0.01 were considered bimodal [144].  Genes with brain-specific expression 
patterns were identified by binarizing expression values with thresholds defined at the 
intersection of the probability density functions of the GMM for each gene [144]. 
Expression values above this threshold are described as "high" or "on". For each gene, 
each observation or sample was modeled as an independent trial in which success was 
defined as expression in the "on" mode.  P-values were calculated from the binomial 
distribution with an equal probability of success and failure.  P-values less than or equal 
to 0.01 indicates a significant association between bimodal gene expression and 
phenotype.  Approximately 542 genes were expressed in the “on” mode in a majority of 
neural tissue samples.   
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Single nucleotide polymorphisms in the coding and regulatory regions of candidate genes 
were identified using annotation information obtained from the NetAffx database 
maintained by Affymetrix.  Probesets on the HGU133A and HGU133plus2 platforms 
mapping to multiple chromosomal regions were excluded from analysis.  This filtering 
step resulted in the exclusion of 35 genes.  Chromosomal regions containing coding and 
cis regulatory regions of candidate genes were conservatively identified using a 1 Mb 
window centered at the midpoint of the sequence at which each probeset aligns [177].  In 
this manner, 55,214 SNPs in candidate gene regions were identified.   
 
6.3.4  Two-stage family-based association test  
 
Family-based association tests (FBATs) use genotypes of parents and affected offspring 
to evaluate the composite null hypothesis of no linkage between disease loci and tested 
loci and no association between genotype and disease phenotype.  The test statistic is a 
generalization of the transmission disequilibrium test (TDT) that compares the frequency 
at which alleles are passed to affected offspring with its expected value derived from 
parental genotypes [197].  Only families with heterozygous parental genotypes are 
informative in the calculation of the test statistic [198].  Given a genetic locus with two 
alternate alleles A and B, the FBAT statistic is calculated as follows:  
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where Tij represents the phenotype  (ie. Tij = 1 if affected, 0 otherwise) and Xij represents 
the genotype of the ith offspring in the jth family [190].  The value of Xij is dependent on 
the genetic model being evaluated.  For example, under an additive model Xij is equal to 
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the number of A alleles (i.e. 0, 1, or 2) in the genotype of the ijth individual [74].  
Simulations have demonstrated that the additive genetic model is robust even in cases of 
dominant or recessive inheritance [74, 199].  With this in mind, we assume that all loci fit 
the additive model.  The expected value of S is calculated conditional on the parental 
genotypes under the assumption of Mendelian inheritance [74].  Under the null 
hypothesis, the FBAT statistic has an approximate standard normal distribution which 
can be used to calculate the significance of the observed test statistic. 
 
A two-stage FBAT strategy was applied to correct for multiple testing in genome-wide 
and candidate gene association studies.  Promising genetic loci are screened by ranking 
the power of the associated FBAT test statistics [198].  Significant associations are more 
likely to be identified at high powered loci in the downstream testing stage.  To maintain 
independence between screening and testing, offspring genotypes in informative families 
(i.e. families in which at least one parent is heterozygous) are replaced by their expected 
value derived from parental genotypes.  In this manner, parental genotypes and offspring 
phenotypes are used to estimate the genetic effect size, and subsequently the power, of 
the FBATs associated with each locus [198].  The second-stage uses the FBAT to 
evaluate observed offspring genotypes and identify loci with significant association with 
phenotype.  Information obtained in the screening stage can be used to select significance 
thresholds and account for multiple testing.  For example, testing the top n loci ranked in 
the screening stage greatly reduces the number of tests and increases the threshold at 
which genome-wide significance is implied (e.g. the top 10 loci can be tested with a 
significance threshold of 0.05/10) [174, 190].  A second strategy partitions the ranked 
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loci into subsets of exponentially increasing size [200].  A significance threshold is 
defined for each subset by multiplying the genome-wide significance level (e.g. 0.05) 
with exponentially decreasing weights (Table 11).  In this manner, all genetic loci can be 
tested for association without neglecting the information gained in the screening stage.  In 
our analysis, we have adopted the latter method.  
 
 
Table 11: Adjusted significance level determined by rank in screening step 
 
Rank of Loci in 
Screening 
Adjusted 
Significance Level 
5 0.005 
15 1.25E-03 
35 3.12E-04 
75 7.81E-05 
155 1.95E-05 
315 4.88E-06 
635 1.22E-06 
1,275 3.05E-07 
2,555 7.63E-08 
5,115 1.90E-08 
10,235 4.77E-09 
20,475 1.19E-09 
40,955 2.98E-10 
 
 
 
6.3.5 Assessment of linkage disequilibrium patterns 
 
Linkage disequilibrium (LD) patterns in the multiplex cohort were analyzed to identify 
potential autism risk loci correlated with significant screened SNPs.  Linkage 
disequilibrium is defined as the statistical association between two or more genetic loci 
and is calculated in a pairwise manner [201].  Consider two biallelic SNPs, in which two 
genetic variations are present at each locus, there are four potential haplotypes (i.e. snp1= 
A1/B1, snp2 = A2/B2, haplotypes = A1A2, A1B2, B1A2, B1B2).  In the absence of LD, the 
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expected frequency of the four haplotypes converges to the product of the constituent 
allele frequencies.  Disequilibrium between the two loci can be calculated as:  
( ) )()( 2121 APAPAAPD −=  
 
in which P(.) is the frequency of the corresponding haplotypes and alleles [202].  The D 
statistic is dependent on the allele frequencies in the population.  A normalized measure 
of LD (D’) can be obtained by dividing D by its maximum value where  
( ) ( ) ( ) ( )( )2121max ,min APBPBPAPD =  
 
The value of D’ ranges from zero to one.  Higher values correspond to higher 
disequilibrium.  Pairs of genetic loci are said to be in strong LD if the one-sided upper 
95% confidence bound of D’ is greater than 0.98 and the lower bound is greater than 0.7 
[201].  Conversely, loci with strong evidence of recombination can be identified by an 
upper confidence bound less than 0.7 [201].  A disequilibrium block is defined as a 
region over which less than 5% of pairwise comparisons show strong evidence of 
recombination [201].  The Haploview software package [203] was used to identify LD 
blocks in genotype data in the proximity of SNPs significantly associated with autism.   
 
 
6.4 Results  
 
6.4.1 Chromosomal location of candidate gene regions and SNPs tested for 
association 
 
Candidate genes for autism-susceptibility loci were identified using gene expression 
analysis of an expression microarray dataset composed of 400 tissue samples and 19 
different phenotypes.  Neural-specific switch-like genes were identified with the 
following properties: the expression profile across all samples fits a bimodal distribution 
and expression is measured in the “high” mode in a majority of 89 samples of brain 
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tissue.  A set of 542 neural-specific switch-like genes were identified that meet these 
specifications.  Figure 20 maps the chromosomal location of the coding and putative cis-
regulatory regions of these genes as red bars to the left of the chromosome ideograms.  
Regulatory regions were conservatively identified using a 1 M base pair window centered 
at the midpoint of the gene coding region, as described  
 
 
 
 
Figure 20: Karyogram depicting the chromosomal location of 542 neural-specific 
switch-like genes and 55,214 SNPs – Red bars to the left of the ideograms indicate the 
coding and putative regulatory regions of the identified neural-specific bimodal genes. 
Black arrows indicate the location of SNPs within these chromosomal regions.  
 
 
 
[177].  Approximately 55,200 SNPs on the Affymetrix Genome-Wide Human SNP Array 
5.0 platform are located in these chromosomal regions.  Chromosomal locations of these 
SNPs are indicated in Figure 1 by black arrows.  Candidate genes and associated SNPs 
are well-distributed throughout the autosomal and X chromosomes.  Approximately 86% 
of the SNPs on the array were excluded through the use of the candidate gene approach.  
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6.4.2 SNP rs17101921 is an autism susceptibility locus 
  
Association tests of SNPs in candidate gene regions identified an autism-susceptibility 
locus in the q26 region of chromosome 10.  A two-stage FBAT strategy was used to test 
all of the loci in the candidate gene regions for association under an additive genetic 
model and correct for multiple testing.  In the initial screening stage, loci were ranked 
according to estimates of statistical power of the corresponding association test.  In the 
downstream testing stage, loci are tested for association with the FBAT statistic.  The 
threshold for genome-wide significance for a genetic locus is determined by its rank in 
the screening stage (Table 11).  Following this methodology, rs17101921 reached 
genome-wide significance (p-value = 0.0038; Table 12).  Table 12 gives the rank in the 
screening stage, reference SNP identifier, minor allele frequency, FBAT p-value, 
genome-wide significance threshold and odds ratio for rs17101921 and adjacent SNPs on 
chromosome 10 represented on the Affymetrix chip.  Individuals with the rs17101921 A 
allele are more likely to be autistic [odds ratio (OR) = 1.31, 95% confidence interval (CI) 
(0.81-2.11)].  In addition, none of the adjacent SNPs on the Affymetrix chip 
demonstrated significant association with autism susceptibility (Table 12).  Association 
tests indicate that rs17101921 is a marker for autism risk.  
 
6.4.3 Linkage disequilibrium analysis identifies a small haplotype block containing 
SNP rs17101921 
 
We assessed linkage disequilibrium (LD) patterns around SNP rs17101921 to identify 
genetic variants that tend to be inherited with rs17101921 in haplotype blocks.  Figure 21 
shows a LD plot of SNPs on the Affymetrix chip in a ~125 kB region centered on the 
rs17101921 locus.  The low LD between many pairs of loci indicates the rate of
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Table 12: SNP rs17101921 associated with autism susceptibility- 47625 SNPs were 
tested for association with autism using a two-stage FBAT strategy.  SNP rs17101921 in 
bold below passed the FBAT with genome-wide significance.  Tested SNPs adjacent to 
rs17101921 were not significant.  MAF = minor allele frequency, OR = odds ratio.  
 
Rank in 
Screen SNP MAF 
FBAT 
Pvalue 
Significance 
Level OR 
6392 rs1896404 0.418 0.283 4.77E-09 0.9 (0.6-1.34) 
470 rs2420929 0.131 0.2998 1.22E-06 2.51 (0.64-9.79) 
5 rs17101921 0.05 0.0038 0.005 1.31 (0.81-2.11) 
18895 rs9421422 0.485 0.4642 1.19E-09 0.84 (0.56-1.25) 
9733 rs4457689 0.092 0.1514 4.77E-09 0.66 (0.21-2.02) 
 
 
 
Table 13: Chromosomal location of rs17101921 and adjacent SNPs 
  
SNP Allele Chromosome Base Pair Location 
rs1896404 T/A 10 123131120 INTERGENIC 
rs2420929 T/C 10 123143166 INTERGENIC 
rs17101921 G/A 10 123143285 INTERGENIC 
rs4457689 G/A 10 123166119 INTERGENIC 
rs9421422 C/G 10 123144178 INTERGENIC 
 
 
 
recombination in the region is high.  SNP rs17101921 is located on a small LD block 
spanning ~13 kB consisting of four tested SNPs on the Affymetrix array, including 
rs9420328, rs1896404, rs2420929, and rs9421422.  Although none of these SNPs 
demonstrated individual association with autism, testing the inheritance of the haplotype 
block as a whole may produce significant results.  It should also be noted that rs17101921 
may be in LD with SNPs that are not represented on the Affymetrix array.  The dbSNP 
database identifies 97 SNPs in the same 13 kB region.  Genotyping the chromosomal 
region at higher resolution will reveal a more detailed picture of linkage disequilibrium 
structure.
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Figure 21: Linkage disequilibrium plot of the chromosomal region around 
rs17101921 – Pair-wise linkage disequilibrium between two SNPs is indicated by the 
color of the associated square along the diagonal.  The red asterisk in the linkage 
disequilibrium plots identifies SNP rs17101921.  Top figure: An ideogram of 
chromosome 10.  The region mapped for linkage disequilibrium is indicated by the red 
bar.  Bottom figure: A linkage disequilibrium plot of a ~125 kB region around SNP 
rs17101921.  Linkage disequilibrium is quantified by D’. 
 
 
 
6.4.4 Genes located within the q26 region of chromosome 10 
  
To investigate potential functional implications of genetic variation at SNP rs17101921, 
we identified genes with coding regions located within the 1MB window around the 
genetic locus.  The rs17101921 SNP is found in an intergenic region in the short arm of 
chromosome 10 (Table 13).  Seven genes lie within this chromosomal region (Table 14).  
Table 14 lists the Entrez Gene identifiers, gene symbols, base pair locations of the start 
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and end of the coding regions, and the identifier of the genes in the Online Mendelian 
Inheritance in Man (OMIM) database for these genes.   Of the genes in the proximity of 
rs17101921, fibroblast growth factor receptor 2 (FGFR2) is the closest (~80 Kb 
downstream).  The FGFR2 gene is also among the neural-specific switch-like genes used 
to identify candidate gene regions.  These results suggest that autism susceptibility may 
be related to altered expression or function of FGFR2 as a result of genetic variation at 
rs17101921.
 
 
Table 14: Genes within 1Mb of rs17101921- Coding regions of seven genes are located 
within 1Mb of rs17101921.  Fibroblast growth factor receptor 2 (FGFR2) in bold below 
is the closest to rs17101921 (~80Kb downstream) and is also a neural-specific bimodal 
gene.   
 
Entrez Gene ID Gene Symbol Start End OMIM ID 
196051 PPAPDC1A 122206456 122339357  
55717 BRWD2 122600860 122659025 606417 
2263 FGFR2 123223889 123347962 176943 
11101 ATE1 123492616 123677936 607103 
54780 NSMCE4A 123706601 123724722  
10579 TACC2 123738699 124004049 605302 
118663 BTBD16 124020811 124087666  
 
 
 
6.5 Discussion 
 
In this study, we have found a significant association between autism and genetic 
variation at a single genetic locus in an intergenic region of chromosome 10 in a cohort of 
189 multiplex autism-affected families.  Several measures were adopted to reduce the 
severity of multiple testing corrections applied to family-based association tests.  In 
previous work, we identified a set of neural-specific switch-like genes with bimodal 
expression patterns and known involvement in nervous system development and 
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function.  Using the coding and cis-regulatory regions of these genes as candidate 
association loci resulted in the reduction of the SNP feature space by 86%.  A two-stage 
family-based association test was used for association testing [200].   In this procedure, 
SNPs are first ranked according to the probability that a significant association will be 
found and then tested for association with the significance threshold dependent on the 
rank in the screening stage.  With this method, SNP rs17101921 was identified as an 
autism-susceptibility locus with genome-wide significance (p-value = 0.0038; threshold = 
0.005).     Individuals with the A allele at this locus were found to be at greater risk for 
developing autism [OR = 1.31, CI (0.81-2.11)].  Linkage disequilibrium analysis 
localizes rs17101921 to a small haplotype block consisting of four other SNPs on the 
Affymetrix array (rs9420328, rs1896404, rs2420929, and rs9421422).  In addition, 
rs17101921 is located approximately 80 kB upstream from FGFR2, a growth factor 
receptor involved in neurodevelopment and neural function.   
 
Linkage between genomic regions on chromosome 10 and neurological disorders has 
been observed in a number of previously published studies.  A significant (p-value < 
0.01) quantitative trait locus linked to social responsiveness scores was identified in a 
genomic screen of 62 families with male autistic children [204].  Similarly, a quantitative 
trait locus linked to a measure of language development, age at first phrase, was detected 
(p-value = 0.018) in a study of 152 multiplex families [205].  A third study identified 
autism-linked genetic loci at two locations along chromosome 10 (10p14; 10q23.31; p-
values not given) in an analysis of affected families showing elevated obsessive-
compulsive traits [206].  A meta-analysis of data from five independent genome scans 
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identified several loci (10p12-q11.1, p-value = 0.0022; 10q11.2-q23, p-value = 0.0299; 
10q22-q23, p-value = 0.0432) linked with nominal significance to risk for autism-
spectrum disorders [184].  In addition, linkage has been reported between the 10q26 
region and a number of other neurological disorders, including schizophrenia [207, 208], 
bipolar disorder [208] and Alzheimer’s disease [209].  These studies, along with our 
findings, provide evidence of the involvement of genetic loci on chromosome 10 in 
conferring autism susceptibility and suggest the possibility of common molecular 
mechanisms in autism, schizophrenia, bipolar disorder and Alzheimer’s disease.    
 
Genetic variation at rs17101921 may influence the expression of fibroblast growth factor 
receptor 2 (FGFR2) located approximately 80 kB downstream.  Genomic screens for 
expression quantitative trait loci (eQTL), have established that genetic variants up to 100 
kB from the coding region can influence gene expression [176, 177].  Fibroblast growth 
factor receptors are transmembrane proteins with an intracellular tyrosine kinase domain.  
Ligand binding induces dimerization and receptor activation by phosphorylation of the 
intracellular domain [192].  Signaling through fibroblast growth factor receptors activates 
a number of downstream processes including proliferation, cell-cycle progression and 
cytoskeletal remodeling[192].  Fibroblast growth factor receptor 2 (FGFR2) is highly 
expressed in glial cells in the brain [210].  In both the developing and adult brain, 
expression of fibroblast growth factor-2 (FGF2) increases the proliferation of neurons 
and neural stem cells, stimulates axon branching, and has a neuroprotective function in 
brain injury and ischemia [192].  Larger brain size at age 2-4, increased glial cell 
activation and excessive neural degeneration later in life are all characteristics of autism 
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[211, 212].  Altered regulation of FGFR2 expression could be a contributing factor in all 
of these conditions.  In addition, mutation of the FGFR2 gene has been associated with a 
number of developmental disorders including craniosyntosis and Crouzon syndrome 
which presents with mental disabilities [213].  These findings suggest that increased 
autism risk transmitted by variation at the rs17101921 locus is potentially related to 
expression of the FGFR2 gene.  
 
6.6 Conclusion  
 
We detected an autism susceptibility locus, SNP rs17101921, through family-based 
association testing of genomic data obtained from a cohort of 189 mulitplex families in 
the AGRE database.  Candidate gene regions were identified using neural-specific 
bimodal expression patterns identified from gene expression analysis of a large, 
phenotypically diverse compilation of microarray data.  The positive results of this 
approach validate future study of genetic variation in candidate gene regions identified 
from microarray analysis.  Functional characterization of the genetic variant is frustrated 
by localization to an intergenic chromosomal region; however, a potential link is 
established through the FGFR2 gene.  Analysis of gene expression data linked to 
genotype information could be used to verify this connection.  Results justify further 
analysis of the 10q26 chromosomal region with genotyping at higher resolution.   In 
addition, a screen for quantitative trait loci associated with traits such as social 
responsiveness, language development or repetitive behaviors may result in a genomic 
screen with greater statistical power.   
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Chapter 7: Conclusion  
Technological advances in the post-genomic era of biological study have provided a 
higher resolution picture of gene regulation and the perturbations that characterize 
complex phenomena such as development, differentiation and chronic disease.  High-
throughput sequencing platforms and gene expression microarrays provide the means to 
profile biological systems from the genomic and transcriptomic perspectives.  In addition, 
shared public databases catalog the sequence, structure and function of genes and 
proteins and organize them into coherent ontologies and interaction models.  The 
abundance of data available allows for an unbiased, holistic approach to investigation.  
Significant results can be used to gain new insight and generate original testable 
hypotheses.  Conversely, the high dimensionality of genome-scale datasets makes it 
difficult to identify relevant information from noise.  In this work, we integrated prior 
knowledge, gene functional information, and genome-scale microarray data across two 
modalities with classification methodologies to extract meaningful biological information 
from high dimensional microarray datasets. 
 
In the study of cancer, gene expression microarray analysis has been used to identify 
expression biomarkers that either classify samples into clinically homogenous subtypes 
or predict the course of disease.  With extensive use of this methodology, it was observed 
that multiple biomarker sets generated from independent studies of the same disease state 
share few common genes.  We developed an iterative supervised classification approach 
to generate populations of biomarker sets that could be evaluated for predictive potential.  
Results indicate that many biomarker sets accurately classify cancer samples.  A possible 
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biological explanation for the lack of agreement between biomarker panels is the 
redundancy observed in cellular signaling pathways.  This explanation is supported by 
analyses that demonstrate more consistent results when comparing independent datasets 
by the expression of functional sets of genes rather than individual genes [92].  Technical 
variability between microarray platforms may also play a role.  To investigate this 
possibility, we assessed the classification accuracy of expression biomarker panels on 
independent datasets both within and across microarray platforms.  Predictive accuracy 
decreased and was more variable when panels were tested across platforms, indicating 
that technical variability is a significant issue.  Studies analyzing the reproducibility of 
microarray expression values in multi-center trials have indicated that technical 
variability can be adequately controlled by proper experimental design [214].  
 
Large-scale compilation of gene expression datasets in public repositories provides the 
opportunity to investigate patterns of gene expression across diverse biological 
phenotypes.  A number of studies have used gene expression analysis to identify house-
keeping genes ubiquitously expressed across different tissue types and presumably 
required for normal cellular function [132, 133].  Similarly, switch-like genes with 
bimodal expression profiles have been identified [134, 144].  We used a number of 
classification methods to investigate the expression of switch-like genes in datasets of 
diverse phenotypes in health and disease.  Use of a model-based classification method 
resulted in accurate classification of tissues into groups corresponding to 19 different 
tissue types.  Similar accuracy was obtained with a multi-class supervised classification 
method.  These results suggest that identification of switch-like genes may be an effective 
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method to reduce the size of the feature space in gene expression analysis.  Model-based 
and supervised methods also produced accurate classification of samples in a dataset 
profiling blood cells from subjects with one of four infectious diseases.  A number of 
studies have observed unique expression changes in peripheral blood cells of the immune 
system in response to different pathogens [215, 216].   The biological relevance of 
bimodal expression patterns is implied by functional enrichment analysis of the activated 
switch-like genes in different phenotypes.  In tissues including the brain, and skeletal and 
cardiac muscle, activated switch-like genes are enriched for tissue-specific functions.  
Similarly, in infectious disease activated genes are enriched with functions related to the 
immune response.  In light of these results, switch-like genes appear to be involved in 
specialized or temporally active biological processes.  Identification and characterization 
of switch-like genes as well as the phenotypes in which they are activated will have 
important implications in fields such as stem cell research, tissue engineering and gene 
therapy.   
 
Genetic variation at the gene sequence level can result in differences in the expression 
and function of gene products that contribute to increased risk of disease.  Single 
nucleotide polymorphisms have been associated with a number of common pathological 
conditions including obesity [174], diabetes [34, 175], inflammatory bowel disease [34, 
173], and cardiovascular disease [34, 172].  Using information gained from analysis of 
switch-like expression patterns, we detected a single nucleotide polymorphism in an 
intergenic region of chromosome 10 associated with increased susceptibility to autism.  
Notably, the same chromosomal region has been linked to other neurological diseases 
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including bipolar disorder [208], schizophrenia [207, 208] and Alzheimier’s disease 
[209].   The functional implications of genetic variation in gene coding regions are 
assessed by examining sequence, structure and evolutionary conservation of homologous 
proteins [75, 76].  Less is known about the effects of variation in non-coding regions; 
however the increased autism risk transmitted by the genetic variant identified in our 
analysis may be related to altered expression of the fibroblast growth factor receptor 2 
gene.   Analysis of genomic and transcriptomic data from a set of autistic individuals to 
validate this hypothesis is warranted.  In addition, identification of the autism 
susceptibility locus in this analysis motivates the development of more direct methods for 
the integration of gene expression and gene mapping microarray datasets.
  
117 
List of References 
 
 
 
 
1. Loden M, van Steensel B: Whole-genome views of chromatin structure. 
Chromosome Res 2005, 13:289-298. 
 
2. Rothkamm K, Gunasekara K, Warda SA, Krempler A, Lobrich M: Radiation-
induced HPRT mutations resulting from misrejoined DNA double-strand 
breaks. Radiat Res 2008, 169:639-648. 
 
3. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, 
Summerfield JA: Mutation of gene of mannose-binding protein associated 
with chronic hepatitis B viral infection. Lancet 1996, 348:1417-1419. 
 
4. Pollard TD, Earnshaw WC: Cell Biology. Philadelphia: Elsevier 2004. 
 
5. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F: Rac1 activation 
controls nuclear localization of beta-catenin during canonical Wnt signaling. 
Cell 2008, 133:340-353. 
 
6. Veselik DJ, Divekar S, Dakshanamurthy S, Storchan GB, Turner JM, Graham 
KL, Huang L, Stoica A, Martin MB: Activation of estrogen receptor-alpha by 
the anion nitrite. Cancer Res 2008, 68:3950-3958. 
 
7. Wenta N, Strauss H, Meyer S, Vinkemeier U: Tyrosine phosphorylation 
regulates the partitioning of STAT1 between different dimer conformations. 
Proc Natl Acad Sci U S A 2008, 105:9238-9243. 
 
8. Holmberg CI, Tran SE, Eriksson JE, Sistonen L: Multisite phosphorylation 
provides sophisticated regulation of transcription factors. Trends Biochem Sci 
2002, 27:619-627. 
 
9. Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet 2002, 
30:13-19. 
 
10. Lawrence Berkeley National Laboratory Image Library 
[http://acs.lbl.gov/ImgLib/COLLECTIONS/BERKELEY-LAB/RESEARCH-
1991-PRESENT/LIFE-SCIENCES/index/96703355.html] 
 
11. Walsh CT, Garneau-Tsodikova S, Gatto GJ, Jr.: Protein posttranslational 
modifications: the chemistry of proteome diversifications. Angew Chem Int Ed 
Engl 2005, 44:7342-7372. 
 
  
118 
12. Vadaie N, Dionne H, Akajagbor DS, Nickerson SR, Krysan DJ, Cullen PJ: 
Cleavage of the signaling mucin Msb2 by the aspartyl protease Yps1 is 
required for MAPK activation in yeast. J Cell Biol 2008, 181:1073-1081. 
 
13. Bird A: Perceptions of epigenetics. Nature 2007, 447:396-398. 
 
14. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome 
integrates intrinsic and environmental signals. Nat Genet 2003, 33 Suppl:245-
254. 
 
15. Saxonov S, Berg P, Brutlag DL: A genome-wide analysis of CpG dinucleotides 
in the human genome distinguishes two distinct classes of promoters. Proc 
Natl Acad Sci U S A 2006, 103:1412-1417. 
 
16. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, 
and DNA methylation-how does it all fit together? J Cell Biochem 2002, 
87:117-125. 
 
17. Vignali M, Hassan AH, Neely KE, Workman JL: ATP-dependent chromatin-
remodeling complexes. Mol Cell Biol 2000, 20:1899-1910. 
 
18. Shyu AB, Wilkinson MF, van Hoof A: Messenger RNA regulation: to translate 
or to degrade. Embo J 2008, 27:471-481. 
 
19. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD: A 
cellular function for the RNA-interference enzyme Dicer in the maturation of 
the let-7 small temporal RNA. Science 2001, 293:834-838. 
 
20. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim 
S, Kim VN: The nuclear RNase III Drosha initiates microRNA processing. 
Nature 2003, 425:415-419. 
 
21. Peters L, Meister G: Argonaute proteins: mediators of RNA silencing. Mol 
Cell 2007, 26:611-623. 
 
22. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: 
microRNAs can up-regulate translation. Science 2007, 318:1931-1934. 
 
23. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont 
JW, Boudreau A, Hardenbol P, Leal SM, et al: A second generation human 
haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861. 
 
24. A haplotype map of the human genome. Nature 2005, 437:1299-1320. 
 
25. Garrington TP, Johnson GL: Organization and regulation of mitogen-activated 
protein kinase signaling pathways. Curr Opin Cell Biol 1999, 11:211-218. 
  
119 
26. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated 
by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912. 
 
27. Pimienta G, Pascual J: Canonical and alternative MAPK signaling. Cell Cycle 
2007, 6:2628-2632. 
 
28. Junttila MR, Li SP, Westermarck J: Phosphatase-mediated crosstalk between 
MAPK signaling pathways in the regulation of cell survival. Faseb J 2008, 
22:954-965. 
 
29. Shaul YD, Seger R: The MEK/ERK cascade: from signaling specificity to 
diverse functions. Biochim Biophys Acta 2007, 1773:1213-1226. 
 
30. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, 
McGlynn K, Stippec S, Earnest S, et al: The roles of MAPKs in disease. Cell 
Res 2008, 18:436-442. 
 
31. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. 
Hum Mol Genet 2007, 16 Spec No 1:R50-59. 
 
32. Badano JL, Katsanis N: Beyond Mendel: an evolving view of human genetic 
disease transmission. Nat Rev Genet 2002, 3:779-789. 
 
33. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: 
past successes for mendelian disease, future approaches for complex disease. 
Nat Genet 2003, 33 Suppl:228-237. 
 
34. Genome-wide association study of 14,000 cases of seven common diseases and 
3,000 shared controls. Nature 2007, 447:661-678. 
 
35. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM: Expression profiling using 
cDNA microarrays. Nat Genet 1999, 21:10-14. 
 
36. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic 
oligonucleotide arrays. Nat Genet 1999, 21:20-24. 
 
37. Kennedy GC, Matsuzaki H, Dong S, Liu WM, Huang J, Liu G, Su X, Cao M, 
Chen W, Zhang J, et al: Large-scale genotyping of complex DNA. Nat 
Biotechnol 2003, 21:1233-1237. 
 
38. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, 
Aach J, Ansorge W, Ball CA, Causton HC, et al: Minimum information about a 
microarray experiment (MIAME)-toward standards for microarray data. 
Nat Genet 2001, 29:365-371. 
  
120 
39. Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L, Coates G, Cuff 
J, Curwen V, Cutts T, et al: An overview of Ensembl. Genome Res 2004, 
14:925-928. 
 
40. Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: gene-centered 
information at NCBI. Nucleic Acids Res 2005, 33:D54-58. 
 
41. The universal protein resource (UniProt). Nucleic Acids Res 2008, 36:D190-
195. 
 
42. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene 
expression and hybridization array data repository. Nucleic Acids Res 2002, 
30:207-210. 
 
43. Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, 
Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M, et al: ArrayExpress--a 
public database of microarray experiments and gene expression profiles. 
Nucleic Acids Res 2007, 35:D747-750. 
 
44. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, 
Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: tool for the unification 
of biology. The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 
 
45. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. 
Nucleic Acids Res 2000, 28:27-30. 
 
46. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, 
Speed TP: Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 
 
47. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of 
Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15. 
 
48. Statistical algorithms description document [http://www.affymetrix.com/ 
support/technical/whitepapers/sadd_whitepaper.pdf]  
 
49. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization 
methods for high density oligonucleotide array data based on variance and 
bias. Bioinformatics 2003, 19:185-193. 
 
50. Katz S, Irizarry RA, Lin X, Tripputi M, Porter MW: A summarization approach 
for Affymetrix GeneChip data using a reference training set from a large, 
biologically diverse database. BMC Bioinformatics 2006, 7:464. 
 
51. BRLMM: an Improved Genotype Calling Method for the GeneChip Human 
Mapping 500K Array Set  
  
121 
52. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, Sadovsky Y: A 
variable fold change threshold determines significance for expression 
microarrays. Faseb J 2003, 17:321-323. 
 
53. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied 
to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-
5121. 
 
54. Kerr MK, Martin M, Churchill GA: Analysis of variance for gene expression 
microarray data. J Comput Biol 2000, 7:819-837. 
 
55. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems 
JL, Swinkels DW, Witjes JA, Malmstrom PU, de Kok JB: Gene expression 
analysis for the prediction of recurrence in patients with primary Ta 
urothelial cell carcinoma. Eur Urol 2007, 51:416-422; discussion 422-413. 
 
56. Bland JM, Altman DG: Multiple significance tests: the Bonferroni method. 
Bmj 1995, 310:170. 
 
57. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate - a Practical 
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical 
Society Series B-Methodological 1995, 57:289-300. 
 
58. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, Brown PO, 
Botstein D, Futcher B: Comprehensive identification of cell cycle-regulated 
genes of the yeast Saccharomyces cerevisiae by microarray hybridization. 
Mol Biol Cell 1998, 9:3273-3297. 
 
59. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller 
H, Loh ML, Downing JR, Caligiuri MA, et al: Molecular classification of 
cancer: class discovery and class prediction by gene expression monitoring. 
Science 1999, 286:531-537. 
 
60. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen 
H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 
100:8418-8423. 
 
61. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of 
genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-
14868. 
 
62. Medvedovic M, Sivaganesan S: Bayesian infinite mixture model based 
clustering of gene expression profiles. Bioinformatics 2002, 18:1194-1206. 
 
  
122 
63. Ghosh D, Chinnaiyan AM: Mixture modelling of gene expression data from 
microarray experiments. Bioinformatics 2002, 18:275-286. 
 
64. McLachlan GJ, Bean RW, Peel D: A mixture model-based approach to the 
clustering of microarray expression data. Bioinformatics 2002, 18:413-422. 
 
65. Yeung KY, Fraley C, Murua A, Raftery AE, Ruzzo WL: Model-based clustering 
and data transformations for gene expression data. Bioinformatics 2001, 
17:977-987. 
 
66. Joshi A, Van de Peer Y, Michoel T: Analysis of a Gibbs sampler method for 
model-based clustering of gene expression data. Bioinformatics 2008, 24:176-
183. 
 
67. Qin ZS: Clustering microarray gene expression data using weighted Chinese 
restaurant process. Bioinformatics 2006, 22:1988-1997. 
 
68. Simon R: Diagnostic and prognostic prediction using gene expression profiles 
in high-dimensional microarray data. Br J Cancer 2003, 89:1599-1604. 
 
69. Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring 
gene sets in various biological contexts. Nucleic Acids Res 2005, 33:W741-748. 
 
70. Dawn Teare M, Barrett JH: Genetic linkage studies. Lancet 2005, 366:1036-
1044. 
 
71. Pritchard JK, Donnelly P: Case-control studies of association in structured or 
admixed populations. Theor Popul Biol 2001, 60:227-237. 
 
72. Devlin B, Roeder K, Wasserman L: Genomic control, a new approach to 
genetic-based association studies. Theor Popul Biol 2001, 60:155-166. 
 
73. Satten GA, Flanders WD, Yang Q: Accounting for unmeasured population 
substructure in case-control studies of genetic association using a novel 
latent-class model. Am J Hum Genet 2001, 68:466-477. 
 
74. Horvath S, Xu X, Laird NM: The family based association test method: 
strategies for studying general genotype--phenotype associations. Eur J Hum 
Genet 2001, 9:301-306. 
 
75. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res 2003, 31:3812-3814. 
 
76. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and 
survey. Nucleic Acids Res 2002, 30:3894-3900. 
  
123 
77. Chen YW, Zhao P, Borup R, Hoffman EP: Expression profiling in the muscular 
dystrophies: identification of novel aspects of molecular pathophysiology. J 
Cell Biol 2000, 151:1321-1336. 
 
78. Puricelli L, Iori E, Millioni R, Arrigoni G, James P, Vedovato M, Tessari P: 
Proteome analysis of cultured fibroblasts from type 1 diabetic patients and 
normal subjects. J Clin Endocrinol Metab 2006, 91:3507-3514. 
 
79. Barnes MG, Aronow BJ, Luyrink LK, Moroldo MB, Pavlidis P, Passo MH, Grom 
AA, Hirsch R, Giannini EH, Colbert RA, et al: Gene expression in juvenile 
arthritis and spondyloarthropathy: pro-angiogenic ELR+ chemokine genes 
relate to course of arthritis. Rheumatology (Oxford) 2004, 43:973-979. 
 
80. Ma J, Liew CC: Gene profiling identifies secreted protein transcripts from 
peripheral blood cells in coronary artery disease. J Mol Cell Cardiol 2003, 
35:993-998. 
 
81. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek 
M, Angelo M, Reich M, Pinkus GS, et al: Diffuse large B-cell lymphoma 
outcome prediction by gene-expression profiling and supervised machine 
learning. Nat Med 2002, 8:68-74. 
 
82. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber 
GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a 
predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 
 
83. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, 
van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling 
predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 
 
84. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson 
JA, Jr., Marks JR, Nevins JR: Predicting the clinical status of human breast 
cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001, 
98:11462-11467. 
 
85. Dudoit S, Fridlyand J, Speed TP: Comparison of discrimination methods for 
the classification of tumors using gene expression data. Journal of the 
American Statistical Association 2002, 97:77-87. 
 
86. Ben-Dor A, Bruhn L, Friedman N, Nachman I, Schummer M, Yakhini Z: Tissue 
classification with gene expression profiles. Journal of Computational Biology 
2000, 7:559-583. 
 
87. Guyon I, Weston J, Barnhill S: Gene selection for cancer classification using 
support vector machines. Machine Learning 2002, 46:389-422. 
  
124 
88. Li L, Darden TA, Weinberg CR, Levine AJ, Pedersen LG: Gene assessment and 
sample classification for gene expression data using agenetic algorithm/k-
nearest neighbor method. Combinatorial Chemistry and High Throughput 
Screening 2001, 4:727-739. 
 
89. Liu JJ, Cutler G, Li W, Pan Z, Peng S, Hoey T, Chen L, Ling X: Multiclass 
cancer classification and biomarker discovery using GA-based algorithms 
Bioinformatics 2005, 21:2691-2697. 
 
90. Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature genes in 
breast cancer: is there a unique set? Bioinformatics 2005, 21:171-178. 
 
91. Fortunel NO, Otu HH, Ng HH, Chen J, Mu X, Chevassut T, Li X, Joseph M, 
Bailey C, Hatzfeld JA, et al: Comment on " 'Stemness': transcriptional 
profiling of embryonic and adult stem cells" and "a stem cell molecular 
signature". Science 2003, 302:393; author reply 393. 
 
92. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, 
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550. 
 
93. Wang H, He X, Band M, Wilson C, Liu L: A study of inter-lab and inter-
platform agreement of DNA microarray data. BMC Genomics 2005, 6:71. 
 
94. Zakharkin SO, Kim K, Mehta T, Chen L, Barnes S, Scheirer KE, Parrish RS, 
Allison DB, Page GP: Sources of variation in Affymetrix microarray 
experiments. BMC Bioinformatics 2005, 6:214. 
 
95. Baker SG, Kramer BS: Identifying genes that contribute most to good 
classification in microarrays. BMC Bioinformatics 2006, 7:407. 
 
96. Grate LR: Many accurate small-discriminatory feature subsets exist in 
microarray transcript data: biomarker discovery. BMC Bioinformatics 2005, 
6:97. 
 
97. Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with 
microarrays: a multiple random validation strategy. Lancet 2005, 365:488-
492. 
 
98. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd 
HW, Cogliatti SB, Dierlamm J, Feller AC, et al: A biologic definition of 
Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J 
Med 2006, 354:2419-2430. 
 
  
125 
99. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, 
Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human 
breast cancer predicts mutation status, transcriptional effects, and patient 
survival (vol 102, pg 13550, 2005). Proc Natl Acad Sci U S A 2005, 102:17882-
17882. 
 
100. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, 
Pasqualucci L, Neuberg D, Aguiar RC, et al: Molecular profiling of diffuse 
large B-cell lymphoma identifies robust subtypes including one characterized 
by host inflammatory response. Blood 2005, 105:1851-1861. 
 
101. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, 
Timmermans M, Meijer-van Gelder ME, Yu J, et al: Gene-expression profiles to 
predict distant metastasis of lymph-node-negative primary breast cancer. 
Lancet 2005, 365:671-679. 
 
102. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD: Gene 
expression profiling predicts survival in conventional renal cell carcinoma. 
PLoS Med 2006, 3:e13. 
 
103. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight 
SS, Kaloper M, Weng S, Jin H, Ball CA, et al: The Stanford Microarray 
Database. Nucleic Acids Res 2001, 29:152-155. 
 
104. Ihaka R, Gentleman R: R: a language for data analysis and graphics. J Comput 
Graph Stat 1996, 3:299-314. 
 
105. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, 
Gautier L, Ge Y, Gentry J, et al: Bioconductor: open software development for 
computational biology and bioinformatics. Genome Biol 2004, 5:R80. 
 
106. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein 
D, Altman RB: Missing value estimation methods for DNA microarrays. 
Bioinformatics 2001, 17:520-525. 
 
107. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees 
CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA: SOURCE: a unified 
genomic resource of functional annotations, ontologies, and gene expression 
data. Nucleic Acids Res 2003, 31:219-223. 
 
108. Wheeler DL, Chappey C, Lash AE, Leipe DD, Madden TL, Schuler GD, 
Tatusova TA, Rapp BA: Database resources of the National Center for 
Biotechnology Information. Nucleic Acids Res 2000, 28:10-14. 
 
109. GeneChip expression data analysis fundamentals. 
  
126 
110. Molinaro AM, Simon R, Pfeiffer RM: Prediction error estimation: a 
comparison of resampling methods. Bioinformatics 2005, 21:3301-3307. 
 
111. Ingenuity Pathways Analysis [http://www.ingenuity.com/] 
 
112. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L: The use of receiver 
operating characteristic curves in biomedical informatics. J Biomed Inform 
2005, 38:404-415. 
 
113. Macskassy S, Provost R, Rosset S: Confidence bands for ROC curves: 
methods and an empirical study In Proceedings of the 22nd Internationl 
Conference on Machine Learning; Bonn, Germany 2005 
 
114. Bura E, Pfeiffer RM: Graphical methods for class prediction using dimension 
reduction techniques on DNA microarray data. Bioinformatics 2003, 19:1252-
1258. 
 
115. Reiner A, Yekutieli D, Benjamini Y: Identifying differentially expressed genes 
using false discovery rate controlling procedures. Bioinformatics 2003, 
19:368-375. 
 
116. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, 
Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated 
with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-
5984. 
 
117. Bjornstrom L, Sjoberg M: Mechanisms of estrogen receptor signaling: 
convergence of genomic and nongenomic actions on target genes. Mol 
Endocrinol 2005, 19:833-842. 
 
118. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R: BCL-6, a POZ/zinc-finger 
protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U 
S A 1996, 93:6947-6952. 
 
119. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, Louie DC, Offit 
K, Chaganti RS, Dalla-Favera R: BCL-6 protein is expressed in germinal-
center B cells. Blood 1995, 86:45-53. 
 
120. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, 
Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of 
the molecular classification of diffuse large B-cell lymphoma by 
immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282. 
 
121. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani 
R, Levy R: Expression of a single gene, BCL-6, strongly predicts survival in 
patients with diffuse large B-cell lymphoma. Blood 2001, 98:945-951. 
  
127 
122. Bland JM, Altman DG: Survival probabilities (the Kaplan-Meier method). 
Bmj 1998, 317:1572. 
 
123. Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P, Wetmore DZ, 
Mariani TJ, Kohane IS, Szallasi Z: Sequence-matched probes produce 
increased cross-platform consistency and more reproducible biological 
results in microarray-based gene expression measurements. Nucleic Acids Res 
2004, 32:e74. 
 
124. Choi JK, Yu U, Kim S, Yoo OJ: Combining multiple microarray studies and 
modeling interstudy variation. Bioinformatics 2003, 19 Suppl 1:i84-90. 
 
125. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E: A cross-study 
comparison of gene expression studies for the molecular classification of lung 
cancer. Clin Cancer Res 2004, 10:2922-2927. 
 
126. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis 
of microarrays: interstudy validation of gene expression profiles reveals 
pathway dysregulation in prostate cancer. Cancer Res 2002, 62:4427-4433. 
 
127. Li L, Chen L, Goldgof D, George F, Chen Z, Rao A, Cragun J, Sutphen R, 
Lancaster J: Integration of clinical information and gene expression profiles 
for prediction of chemo-response for ovarian cancer. Conf Proc IEEE Eng 
Med Biol Soc 2005, 5:4818-4821. 
 
128. Pittman J, Huang E, Dressman H, Horng CF, Cheng SH, Tsou MH, Chen CM, 
Bild A, Iversen ES, Huang AT, et al: Integrated modeling of clinical and gene 
expression information for personalized prediction of disease outcomes. Proc 
Natl Acad Sci U S A 2004, 101:8431-8436. 
 
129. Sun Y, Goodison S, Li J, Liu L, Farmerie W: Improved breast cancer prognosis 
through the combination of clinical and genetic markers. Bioinformatics 2007, 
23:30-37. 
 
130. Arora A, Simpson DA: Individual mRNA expression profiles reveal the effects 
of specific microRNAs. Genome Biol 2008, 9:R82. 
 
131. Hobert O: Gene regulation by transcription factors and microRNAs. Science 
2008, 319:1785-1786. 
 
132. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee 
KF, Clark KE, Haverty P, et al: A compendium of gene expression in normal 
human tissues. Physiol Genomics 2001, 7:97-104. 
 
  
128 
133. Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M: Comparison of 
human adult and fetal expression and identification of 535 
housekeeping/maintenance genes. Physiol Genomics 2000, 2:143-147. 
 
134. Ertel A, Tozeren A: Human switch-like genes and their regulation via 
transcription initiation and histone methylation. BMC Genomics 2008. 
 
135. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, 
Sabet H, Tran T, Yu X, et al: Distinct types of diffuse large B-cell lymphoma 
identified by gene expression profiling. Nature 2000, 403:503-511. 
 
136. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ: Broad 
patterns of gene expression revealed by clustering analysis of tumor and 
normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S 
A 1999, 96:6745-6750. 
 
137. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM: Systematic 
determination of genetic network architecture. Nat Genet 1999, 22:281-285. 
 
138. Toronen P, Kolehmainen M, Wong G, Castren E: Analysis of gene expression 
data using self-organizing maps. FEBS Lett 1999, 451:142-146. 
 
139. Medvedovic M, Yeung KY, Bumgarner RE: Bayesian mixture model based 
clustering of replicated microarray data. Bioinformatics 2004, 20:1222-1232. 
 
140. Fan J, May SJ, Zhou Y, Barrett-Connor E: Bimodality of 2-h plasma glucose 
distributions in whites: the Rancho Bernardo study. Diabetes Care 2005, 
28:1451-1456. 
 
141. Lim TO, Bakri R, Morad Z, Hamid MA: Bimodality in blood glucose 
distribution: is it universal? Diabetes Care 2002, 25:2212-2217. 
 
142. Maclean CJ, Morton NE, Elston RC, Yee S: Skewness in commingled 
distributions. Biometrics 1976, 32:695-699. 
 
143. Dempster AP, Laird NM, Rubin DB: Maximum likelihood from incomplete 
data via the EM alogrithm Journal of the Royal Statistical Society 1977, 39:1-
38. 
 
144. Ertel A, Tozeren A: Switch-like genes populate cell communication pathways 
and are enriched for extracellular proteins. BMC Genomics 2008, 9:3. 
 
145. Hartigan JA, Wong MA: A K-means clustering algorithm Applied Statistics 
1979, 28:100-108. 
  
129 
146. Tibshirani R, Walther G, Hastie T: Estimating the number of clusters in a data 
set via the gap statistic. Journal of the Royal Statistical Society Series B-
Statistical Methodology 2001, 63:411-423. 
 
147. Hoff PD: Model-based subspace clustering. Bayesian Analysis 2006, 1:321-344. 
 
148. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd 
C, Reich M, Latulippe E, Mesirov JP, et al: Multiclass cancer diagnosis using 
tumor gene expression signatures. Proc Natl Acad Sci U S A 2001, 98:15149-
15154. 
 
149. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002, 
110:673-687. 
 
150. Wheelock MJ, Johnson KR: Cadherin-mediated cellular signaling. Curr Opin 
Cell Biol 2003, 15:509-514. 
 
151. De Arcangelis A, Georges-Labouesse E: Integrin and ECM functions: roles in 
vertebrate development. Trends Genet 2000, 16:389-395. 
 
152. Nelson CM, Bissell MJ: Of extracellular matrix, scaffolds, and signaling: 
tissue architecture regulates development, homeostasis, and cancer. Annu Rev 
Cell Dev Biol 2006, 22:287-309. 
 
153. Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R: Involvement of 
alpha6beta4 integrin in the mechanisms that regulate breast cancer 
progression. Breast Cancer Res 2007, 9:203. 
 
154. Buttery RC, Rintoul RC, Sethi T: Small cell lung cancer: the importance of the 
extracellular matrix. Int J Biochem Cell Biol 2004, 36:1154-1160. 
 
155. van Horssen J, Dijkstra CD, de Vries HE: The extracellular matrix in multiple 
sclerosis pathology. J Neurochem 2007, 103:1293-1301. 
 
156. Gormley M, Dampier W, Ertel A, Karacali B, Tozeren A: Prediction potential of 
candidate biomarker sets identified and validated on gene expression data 
from multiple datasets. BMC Bioinformatics 2007, 8:415. 
 
157. Yamada S, Nelson WJ: Synapses: sites of cell recognition, adhesion, and 
functional specification. Annu Rev Biochem 2007, 76:267-294. 
 
158. Scherer SS, Arroyo EJ: Recent progress on the molecular organization of 
myelinated axons. J Peripher Nerv Syst 2002, 7:1-12. 
 
159. Janeway CA, Jr., Medzhitov R: Innate immune recognition. Annu Rev Immunol 
2002, 20:197-216. 
  
130 
160. Pasare C, Medzhitov R: Toll-like receptors: linking innate and adaptive 
immunity. Microbes Infect 2004, 6:1382-1387. 
 
161. Guida M, D'Elia G, Benvestito S, Casamassima A, Micelli G, Quaranta M, 
Moschetta R, De Lena M, Lorusso V: Hepatitis C virus infection in patients 
with B-cell lymphoproliferative disorders. Leukemia 2002, 16:2162-2163. 
 
162. Landau DA, Saadoun D, Calabrese LH, Cacoub P: The pathophysiology of HCV 
induced B-cell clonal disorders. Autoimmun Rev 2007, 6:581-587. 
 
163. Lindenschmidt EG, Granato CH, Katzner K, Laufs R: Evidence for limited 
humoral immunoglobulin M antibody response to hepatitis B core antigen 
during acute and chronic hepatitis B virus infections. J Clin Microbiol 1985, 
21:1000-1003. 
 
164. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, Gonindard C, Alric L, 
Vinel JP, Pipy B: Nonstructural 3 protein of hepatitis C virus triggers an 
oxidative burst in human monocytes via activation of NADPH oxidase. J Biol 
Chem 2001, 276:23077-23083. 
 
165. Sarantis H, Gray-Owen SD: The specific innate immune receptor CEACAM3 
triggers neutrophil bactericidal activities via a Syk kinase-dependent 
pathway. Cell Microbiol 2007, 9:2167-2180. 
 
166. Anand AR, Ganju RK: HIV-1 gp120-mediated apoptosis of T cells is regulated 
by the membrane tyrosine phosphatase CD45. J Biol Chem 2006, 281:12289-
12299. 
 
167. Barat C, Tremblay MJ: Engagement of CD43 enhances human 
immunodeficiency virus type 1 transcriptional activity and virus production 
that is induced upon TCR/CD3 stimulation. J Biol Chem 2002, 277:28714-
28724. 
 
168. Perfettini JL, Roumier T, Castedo M, Larochette N, Boya P, Raynal B, Lazar V, 
Ciccosanti F, Nardacci R, Penninger J, et al: NF-kappaB and p53 are the 
dominant apoptosis-inducing transcription factors elicited by the HIV-1 
envelope. J Exp Med 2004, 199:629-640. 
 
169. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, Sethuraman A, 
van de Rijn M, Botstein D, Brown PO, Pollack JR: A DNA microarray survey 
of gene expression in normal human tissues. Genome Biol 2005, 6:R22. 
 
170. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, 
Brown PO: Individuality and variation in gene expression patterns in human 
blood. Proc Natl Acad Sci U S A 2003, 100:1896-1901. 
  
131 
171. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even 
A, Horn-Saban S, Safran M, Domany E, et al: Genome-wide midrange 
transcription profiles reveal expression level relationships in human tissue 
specification. Bioinformatics 2005, 21:650-659. 
 
172. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, West K, 
Kashuk C, Akyol M, Perz S, et al: A common genetic variant in the NOS1 
regulator NOS1AP modulates cardiac repolarization. Nat Genet 2006, 38:644-
651. 
 
173. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart 
AH, Abraham C, Regueiro M, Griffiths A, et al: A genome-wide association 
study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 
314:1461-1463. 
 
174. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE, 
Meitinger T, Hunter D, Hu FB, et al: A common genetic variant is associated 
with adult and childhood obesity. Science 2006, 312:279-283. 
 
175. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, 
Belisle A, Hadjadj S, et al: A genome-wide association study identifies novel 
risk loci for type 2 diabetes. Nature 2007, 445:881-885. 
 
176. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R, Hunt S, 
Kahl B, Antonarakis SE, Tavare S, et al: Genome-wide associations of gene 
expression variation in humans. PLoS Genet 2005, 1:e78. 
 
177. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, 
Bird CP, de Grassi A, Lee C, et al: Relative impact of nucleotide and copy 
number variation on gene expression phenotypes. Science 2007, 315:848-853. 
 
178. Veenstra-Vanderweele J, Christian SL, Cook EH, Jr.: Autism as a paradigmatic 
complex genetic disorder. Annu Rev Genomics Hum Genet 2004, 5:379-405. 
 
179. Chakrabarti S, Fombonne E: Pervasive developmental disorders in preschool 
children: confirmation of high prevalence. Am J Psychiatry 2005, 162:1133-
1141. 
 
180. Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, 
McMahon WM, Petersen PB, Mo A, Ritvo A: The UCLA-University of Utah 
epidemiologic survey of autism: prevalence. Am J Psychiatry 1989, 146:194-
199. 
 
181. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M: 
Autism as a strongly genetic disorder: evidence from a British twin study. 
Psychol Med 1995, 25:63-77. 
  
132 
182. A genomewide screen for autism: strong evidence for linkage to 
chromosomes 2q, 7q, and 16p. Am J Hum Genet 2001, 69:570-581. 
 
183. Cantor RM, Kono N, Duvall JA, Alvarez-Retuerto A, Stone JL, Alarcon M, 
Nelson SF, Geschwind DH: Replication of autism linkage: fine-mapping peak 
at 17q21. Am J Hum Genet 2005, 76:1050-1056. 
 
184. Trikalinos TA, Karvouni A, Zintzaras E, Ylisaukko-oja T, Peltonen L, Jarvela I, 
Ioannidis JP: A heterogeneity-based genome search meta-analysis for autism-
spectrum disorders. Mol Psychiatry 2006, 11:29-36. 
 
185. Ylisaukko-oja T, Alarcon M, Cantor RM, Auranen M, Vanhala R, Kempas E, von 
Wendt L, Jarvela I, Geschwind DH, Peltonen L: Search for autism loci by 
combined analysis of Autism Genetic Resource Exchange and Finnish 
families. Ann Neurol 2006, 59:145-155. 
 
186. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, 
Leboyer M, Bourgeron T: Linkage and association of the glutamate receptor 6 
gene with autism. Mol Psychiatry 2002, 7:302-310. 
 
187. Silverthorn DU: Human Physiology An Integrated Approach. San Francisco: 
Pearson Benjamin Cummins; 2004. 
 
188. Kuemerle B, Zanjani H, Joyner A, Herrup K: Pattern deformities and cell loss 
in Engrailed-2 mutant mice suggest two separate patterning events during 
cerebellar development. J Neurosci 1997, 17:7881-7889. 
 
189. Powell SK, Rao J, Roque E, Nomizu M, Kuratomi Y, Yamada Y, Kleinman HK: 
Neural cell response to multiple novel sites on laminin-1. J Neurosci Res 2000, 
61:302-312. 
 
190. Van Steen K, McQueen MB, Herbert A, Raby B, Lyon H, Demeo DL, Murphy A, 
Su J, Datta S, Rosenow C, et al: Genomic screening and replication using the 
same data set in family-based association testing. Nat Genet 2005, 37:683-691. 
 
191. Autism Genetic Resource Exchange [http://www.agre.org/] 
 
192. Reuss B, von Bohlen und Halbach O: Fibroblast growth factors and their 
receptors in the central nervous system. Cell Tissue Res 2003, 313:139-157. 
 
193. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: a 
revised version of a diagnostic interview for caregivers of individuals with 
possible pervasive developmental disorders. J Autism Dev Disord 1994, 
24:659-685. 
 
  
133 
194. Lord C, Risi S, Lambrecht L, Cook EH, Jr., Leventhal BL, DiLavore PC, Pickles 
A, Rutter M: The autism diagnostic observation schedule-generic: a standard 
measure of social and communication deficits associated with the spectrum of 
autism. J Autism Dev Disord 2000, 30:205-223. 
 
195. Rabbee N, Speed TP: A genotype calling algorithm for affymetrix SNP arrays. 
Bioinformatics 2006, 22:7-12. 
 
196. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller 
J, Sklar P, de Bakker PIW, Daly MJ, Sham PC: PLINK: A tool set for whole-
genome association and population-based linkage analyses. American Journal 
of Human Genetics 2007, 81:559-575. 
 
197. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage 
disequilibrium: the insulin gene region and insulin-dependent diabetes 
mellitus (IDDM). Am J Hum Genet 1993, 52:506-516. 
 
198. Lange C, DeMeo D, Silverman EK, Weiss ST, Laird NM: Using the 
noninformative families in family-based association tests: a powerful new 
testing strategy. Am J Hum Genet 2003, 73:801-811. 
 
199. Tu IP, Balise RR, Whittemore AS: Detection of disease genes by use of family 
data. II. Application to nuclear families. Am J Hum Genet 2000, 66:1341-1350. 
 
200. Ionita-Laza I, McQueen MB, Laird NM, Lange C: Genomewide weighted 
hypothesis testing in family-based association studies, with an application to 
a 100K scan. Am J Hum Genet 2007, 81:607-614. 
 
201. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins 
J, DeFelice M, Lochner A, Faggart M, et al: The structure of haplotype blocks 
in the human genome. Science 2002, 296:2225-2229. 
 
202. Jorde LB: Linkage disequilibrium and the search for complex disease genes. 
Genome Res 2000, 10:1435-1444. 
 
203. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of 
LD and haplotype maps. Bioinformatics 2005, 21:263-265. 
 
204. Duvall JA, Lu A, Cantor RM, Todd RD, Constantino JN, Geschwind DH: A 
quantitative trait locus analysis of social responsiveness in multiplex autism 
families. Am J Psychiatry 2007, 164:656-662. 
 
205. Alarcon M, Cantor RM, Liu J, Gilliam TC, Geschwind DH: Evidence for a 
language quantitative trait locus on chromosome 7q in multiplex autism 
families. Am J Hum Genet 2002, 70:60-71. 
  
134 
206. Buxbaum JD, Silverman J, Keddache M, Smith CJ, Hollander E, Ramoz N, 
Reichert JG: Linkage analysis for autism in a subset families with obsessive-
compulsive behaviors: evidence for an autism susceptibility gene on 
chromosome 1 and further support for susceptibility genes on chromosome 6 
and 19. Mol Psychiatry 2004, 9:144-150. 
 
207. Bulayeva KB, Glatt SJ, Bulayev OA, Pavlova TA, Tsuang MT: Genome-wide 
linkage scan of schizophrenia: a cross-isolate study. Genomics 2007, 89:167-
177. 
 
208. Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B, Nee J, Grunn A, Kanyas K, 
Lerer B, et al: Linkage analysis of psychosis in bipolar pedigrees suggests 
novel putative loci for bipolar disorder and shared susceptibility with 
schizophrenia. Mol Psychiatry 2004, 9:1091-1099. 
 
209. Harold D, Jehu L, Turic D, Hollingworth P, Moore P, Summerhayes P, Moskvina 
V, Foy C, Archer N, Hamilton BA, et al: Interaction between the ADAM12 and 
SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. 
Am J Med Genet B Neuropsychiatr Genet 2007, 144B:448-452. 
 
210. Asai T, Wanaka A, Kato H, Masana Y, Seo M, Tohyama M: Differential 
expression of two members of FGF receptor gene family, FGFR-1 and 
FGFR-2 mRNA, in the adult rat central nervous system. Brain Res Mol Brain 
Res 1993, 17:174-178. 
 
211. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, 
Morgan J: Mapping early brain development in autism. Neuron 2007, 56:399-
413. 
 
212. DiCicco-Bloom E, Lord C, Zwaigenbaum L, Courchesne E, Dager SR, Schmitz 
C, Schultz RT, Crawley J, Young LJ: The developmental neurobiology of 
autism spectrum disorder. J Neurosci 2006, 26:6897-6906. 
 
213. Kan SH, Elanko N, Johnson D, Cornejo-Roldan L, Cook J, Reich EW, Tomkins 
S, Verloes A, Twigg SR, Rannan-Eliya S, et al: Genomic screening of fibroblast 
growth-factor receptor 2 reveals a wide spectrum of mutations in patients 
with syndromic craniosynostosis. Am J Hum Genet 2002, 70:472-486. 
 
214. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de 
Longueville F, Kawasaki ES, Lee KY, et al: The MicroArray Quality Control 
(MAQC) project shows inter- and intraplatform reproducibility of gene 
expression measurements. Nat Biotechnol 2006, 24:1151-1161. 
 
 
 
 
  
135 
215. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, Botstein D, 
Staudt LM, Brown PO, Relman DA: Stereotyped and specific gene expression 
programs in human innate immune responses to bacteria. Proc Natl Acad Sci 
U S A 2002, 99:972-977. 
 
216. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, 
Piqueras B, Banchereau J, Palucka AK, Chaussabel D: Gene expression patterns 
in blood leukocytes discriminate patients with acute infections. Blood 2007, 
109:2066-2077.
  
136 
Vita 
 
 
 
Michael Gormley  
 
Education   
Drexel University, Philadelphia, PA 
 Ph.D. Biomedical Engineering, September 2008 (expected)   
  
Duke University, Durham, NC  
 B.S.E. Biomedical Engineering May 2004  
 
Research Experience 
 
Computational 
 
Drexel University, Philadelphia, PA    
Ph.D. Candidate, 2004-Present 
 
Laboratory 
 
Thomas Jefferson University, Philadelphia, PA   
Research Assistant, 2006-2007 
 
Duke University, Durham, NC 
Research Assistant, 2003-2004 
 
University of Texas, Austin TX 
Research Assistant, 2002 & 2003 
 
Publications 
   
Gormley M, Dampier W, Ertel A, Karacali B, Tozeren A. Prediction 
potential of candidate biomarker sets identified and validated on gene 
expression data from multiple datasets. BMC Bioinformatics 2007, 8:415.  
 
Gormley M, and Tozeren A. Expression profiles of switch-like genes 
accurately classify tissue and infectious disease phenotypes in model-
based classification.  In Press. 
